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Chapter 1
Introduction
1.1 Type 1 Diabetes
There are major two types of Diabetes: 1) Type 1 diabetes and 2) Type 2 Diabetes. People with
Type 1 diabetes cannot produce insulin. People with Type 2 diabetes can produce insulin but are
unable to respond to insulin as they should in normal conditions. Both types of diabetes can lead
to high blood glucose levels later in the disease.
When glucose is present in the blood, Insulin binds with the insulin receptors which are bound to
cell membranes. Once, insulin binds to insulin receptors, tyrosine kinase activates. The cell
signaling molecules like IRS.P13K, PDK1, AKT, AS160 and eventually lead to cell survival and
proliferation. GLUT4 transports from cytoplasm to cell membrane. GLUT4 is an insulin regulatedglucose transporter primarily found in adipose tissue and skeletal muscles. Once GLUT4
transporters open, cells can uptake glucose. Glucose will be used in several ways in cells. Glucose
can make ATP and pyruvate through glycolysis. Pyruvate can convert to lipids through
lipogenesis. Glucose can store as glycogen through glycogenesis. If cells cannot uptake glucose,
all these processes will be affected. Without insulin, Glucose cannot uptake by cells and cells
starved with energy (Jennifer J et al., 2017).
1.1a What is the prevalence

Type 1 diabetes (T1D) is an autoimmune disease usually diagnosed in the early stage of life. TID
patients cannot produce insulin in their body, so they depended on daily exogenous insulin
treatments. It is an enormous burden to both patients and the healthcare system of any country.
This disease accounts for the primary cause of mortality of its patients. (Tao B et al.,2010).
1

There are approximately 1.25 million type 1 diabetic patients in the United States. (National
diabetes statistics report, 2017). It is expected that 5 million people will be diagnosed with type 1
diabetes in the next 5 years and 40,000 people will be diagnosed with type 1 diabetes every year.
According to the National Diabetes statistic report, 20000 people under 20 years have type 1
diabetes. For the same age group, there was a 21% increment in T1D diagnoses in the United States
from 2001 and 2009. Moreover, it expects that 600,000 people under the age of 20 will be
diagnosed with this disease by 2050 with non-hispanic whites having the highest risk of being
diagnosed. T1D isn’t just an epidemic in the United States. People living with T1D are prevalent
all over the world. Out of 3.7 million people living with diabetes in the UK, 10% of them have
Type 1, which is approximately 40,000 people. Twenty-nine thousand children living in the UK
have type 1 diabetes (National diabetes statistics report,2017). Over 300,000 Canadians live with
Type 1 diabetes, of which 33,000 are children between the ages 5 and 18 (National diabetes
statistics report,2017). In the last few years, the rate of type 1 diabetes diagnoses has gone up in
New Zealand by 12%. Approximately, over two million people are living with diabetes in
Argentina, and 7 per 100,000 kids aged between 0-14 are usually diagnosed with TID. Fifty
thousand children and adolescents below 20 years old are diagnosed with T1D in china. Over
100,000 children in India and approximately 35,000 children in Saudi Arabia are living with Type
1 diabetes. (National Diabetes Statistics Report, 2017). By looking through the above statistics,
one can get a clear picture of the diabetes epidemic around the world.
1.1b.The associated cost worldwide

The medical expenditure of diabetic patients is 2.3 times higher than a typical average person.
Insulin treatment is common practice in type 1 and type 2 diabetes, and the cost of insulin has
increased from $100 to $200 per month to $400 to $500 per month, depending on the brand. (Spero
2

et al., 2016). The total cost for diabetes has risen from $245 billion to $327 billion, from 2012 to
2017.It is a 26% increment over the past 5 years. According to Economic Costs of Diabetes in the
U.S. in 2017, increased financial burden, health resources and low productivity played a huge role
in cost increment related to diabetes. When breaking down the cost for medical expenditure,30%
for hospital inpatient care, 30% for medications, 15% antidiabetic agents, 13% physical office
visits were counted (Economic cost of Diabetes in USA,2017, American diabetic association).
Average medical expenses of diabetic patients is $16,752 per year which is 2.3 times higher than
normal nondiabetic person’s medical expenditure (Economic cost of Diabetes in USA,2017,
American diabetic association).
The great effort has been made to prevent type 1 diabetes. Unfortunately, the exact etiology and
pathogenesis of type 1 diabetes are still unknown.
1.1c How is T1D clinically identified

Several methods are used to identify type 1 diabetes in children. One of them is a simple blood
sugar test, with initial screening tests where a higher than 200 milligrams per deciliter (mg/dl) in
blood glucose level is considered as type 1 diabetes. The Glycated hemoglobin (A1C) test indicates
the child's average blood sugar level over the past few months by looking through the percentage
of blood sugar attached to hemoglobin. An AIC level above 6.5 is considered as diabetes. Another
test is a fasting blood sugar test taken after the patient fasts for 24 hours. If fasting blood glucose
level is higher than 126 mg/dl, the patient is considered to have type 1 diabetes. Additional tests
for diabetes include checking antibodies related to type 1 diabetes and checking ketone bodies in
urine.
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Accurate and early diagnosis is playing a crucial role in the treatment of diabetes. However, not
all type 1 diabetic patients show those symptoms. Patients with immunological, self-reactive
antibodies have type 1A diabetes, and if specific pathogenicity is not apparent, they belong to
type1B (idiopathic)diabetes (Gianani R et al., 2010). Even at the onset of type 1 diabetes,70% of
islets contain no insulin. The symptoms appear after 90% of beta cells are lost. An individual who
has had type 1 diabetes for five years, may only be left with insulin-deficient cells. The CD8+ T
cells are the most prominent cells in type of 1 diabetes induction followed by macrophages
(CD68+), CD4+ T cells, B lymphocytes (CD20+), and plasma cells (CD138+) (Willcox A et al.,
2009). The patients have smaller pancreas compared to their age, lower BMI compared to normal
people in their age (Atkinson MA et al., 2013).
Most of the individuals get symptoms of type 1 diabetes-like high blood glucose level and low
insulin level, decades after initial induction (Bonifacio E et al.,2010). It takes time to see visible
symptoms, and within that time, most of the islets get damaged and at the unrecovered stage. It is
marked that C -peptides are decreasing two years before disease onset (Sosenko JM et al.,2010)
and the glucose fluctuation at the beginning (Sosenko JM et al.,2010). It is not clear what is the
critical mass value of β cells, to say as a victim of type 1 diabetes, when need to start exogenous
insulin replacement. The disease onset can be varying from months to years, depending on genetic
susceptibility to the disease, environmental factors, etc. The loss of β-cells may affect the
performance of the remaining beta cells. Maintaining residual islets in function is challenging
because it again depends on genetic factors, age, and how the disease management process works
(Atkinson MA et al., 2013).

4

1.1d. Importance of studying T1D

Type 1 diabetes is also known as juvenile diabetes, which causes the destruction of insulinproducing beta cells in the pancreas. Type 1 diabetes (T1D) is a complex autoimmune disease,
which needs constant medical care with risk reduction strategies and glycemic control. T1D is the
most severe form of diabetes, requiring daily injections of insulin. Even with excellent glucose
control, there is a risk of developing complications regarding diabetes. The high blood sugar level
in type 1 diabetes causes kidney failure, stroke, eye problems, dental disease, nerve damage,
depression, foot problems, etc. The exact causes for the T1D remain unclear. One key to the
prevention of full-blown T1D is the identification of noninvasive, targetable signals that precede
the onset of disease.
Diagnosing diabetes is not very accurate because of some reasons. One reason is that symptoms
take longer to show up in adults than kids, mainly if doctors do not specialize in the condition.
Another reason is that people diagnosed with type 1 diabetes have a healthy and lean weight which
rules out with type 2 diabetes with overweight (Adults Can Get Type 1 Diabetes, Too, reviewed
by Carol DE Sarkissian, 2018).
1.2 Viral infection and autoimmunity
1.2.a Disease Induction

As mentioned above, Type 1 diabetes (T1D) is an autoimmune disease characterized by immune
cell-mediated destruction of pancreatic β cells (Atkinson MA et al.,2001). There are various factors
that influence T1D including genetic factors, environmental factors like toxicants and viruses, etc.
The initial step of induction of autoimmunity can be a virus infection (Bortell et al.,2012). The
different strains of viruses can initiate different adverse effects on beta cells (Roivainen M et
al.,2006). Viruses can unmask beta cells for recognition from CD8+ T cells. CD8+ and T
5

lymphocytes can rapidly kill beta cells by secreting IFN gamma like interferons and upregulating
(MHC) (Foulis AK et al., 1988).
It is known that viruses are mimicking islet antigens and activating autoreactive T cells
(Wucherpfennig KW et al.,2001). There are many cases that are related to virus infection and
autoimmunity. The increase rate of autoimmunity is observed in many diabetic cases and has been
associated with enteroviruses (Stene LC et al.,2010). Enterovirus can initiate islet autoimmunity
and progress to the glycemic stage (Coppieters KT et al.,2010). Furthermore, CVB RNA has been
detected during the onset of type 1 diabetic patients (Andreoletti L et al.,1997). CVB virus was
isolated from a child with diabetic ketoacidosis (Juhela S et al.,2000). By inoculating the
homogenate of a patient's pancreas to a mouse, monkey, and human cells helped to isolate B4
diabetogenic version of Coxsackievirus (Yoon JW et al.,1979). Virus infections activate strong
immune responses. CVB4 infection reportedly induces natural killer cells (NK) within the islets.
Since virus infection can induce Type 1 diabetes (T1D), we used LEW.1WR1 rats as our rat model
to virus mimic PIC induced T1D rat model.
LEW rats are only naturally occurring type 1 diabetes rat models that closely resemble human type
1 diabetes in terms of histology, pathogenesis, lack of sex basis, and MHC class II association
(Wurst W et al.,1988). Type 1 diabetes is both autoimmune and inducible, which is common in
inbred rat strains, like humans who express high-risk MHC II haplotype this is designated
RT1B/Du. Among susceptible rat strains, the most suitable one is LEW.1WR1 strains. About 2.5%
of LEW.1WR1 rats develop TID spontaneously and generally, during early reproductive years,
both sexes are affected in the same way, and islets show insulitis (John P et al.,2005). There are
several types of LEW rat models that are used for T1D studies. The Lewis-Insulin dependent
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diabetes mellitus (LEW-iddm) rats can survive after becoming diabetic and can be used to find
diabetic completions (Matthews CE et al.,2005).

The LEW.1WR1 rats can develop spontaneous T1D diabetes at a low rate (2.5%). But, with Poly
IC induction, LEW.1WR1 rats can readily develop T1D at a high rate (98%).
The rats have MHC II major histocompatibility, class II ‘µ’ haplotype, which generally needs to
become autoimmune diabetes in rats. PBS (Phosphate-buffered saline) dissolved Poly IC (1µg/g
body weight) was intraperitoneally injected to 21-25 days old rats in both sexes on day-3, -2,-1
and with KRV on day 0. Diabetes was diagnosed by plasma blood glucose level(>250mg/dL)
(Mordes J et al., 2009).
The LEW.1WR1 rats develop Type 1 diabetes spontaneously. The rats are very susceptible to
develop Type 1 diabetes with polyinosinic:polycytidylic acid (PIC) followed by the KRV virus
injection. The T1D rats are strongly associated with class II MHC haplotype. The MHC locus is
designated to RT1. The RT1-B/DU and RT1-B/DU are homologous to human HLA-DQ (Ellerman
KE et al.,2000). It was found that locus (Iddm37) locus was responsible for the virus induced type
1 diabetes in LEW.1WR1 rats (Blankenhorn E et al.,2009.)

1.2.b UBD/FAT 10 gene

In the rat, the MHC locus is designated RT1 and the permissive class II haplotype is designated
RT1-B/DU 24. The RT1-B locus is homologous to human HLA-DQ and RT1-D to HLA-DR. The
mutations in UBD gene is associated with susceptibility of virus triggered autoimmune T1D in
LEW.1WR1 rats. The SINE (short interspersed element) is resistant to virus induced T1D and
LEW.1WR1 rat is missing a 59 nucleotides insertion near the promoter of the UBD gene. When
7

the UBD gene in LEW.1WR1 rats was deleted, the results showed that T1D incidences were
significantly reduced. In addition, susceptibility locus iddm37 and iddm14 near to MHC class II
determined the susceptibility to virus induced T1D (Cort L et al., 2014).
The ubiquitin family has grown over the years and basically there are two classes of ubiquitin. The
first class is ubiquitin binding proteins (UBPs) and second class is protein compromises UBD like
proteins which include LC3, SUM (Marshall S et al., 2006), ISG15 (Hochstrasser M et al.,2009).
Ubiquitin can influence protein function without proteolysis. Ubiquitin can regulate insulin
homeostasis, insulin signaling pathway and β cell response to calcium (Rome S et al., 2001). ULM
(Ubiquitin-like molecules) can regulate GLUT4 (Glucose transporter 4) degradation and regulate
response to stored GLUT4 components in adipocytes and muscles (Liu LB et al.,2007).
FAT 10 is a pleiotropic UBL protein which has a role to play in cellular localization and fate of
proteins (Bedford L et al., 2011). UBD (Ubiquitin D) or FAT 10 has 76 amino residues and makes
peptide bonds with free C- terminal and glycine with alpha amino group of lysine at target end.
The experiments were done with FAT10 ko mice and looked at age related metabolic changes of
these rats. The Glucose tolerance test and insulin tolerance test were performed during the
experiment period. Those FAT10 ko mice lived longer than the control group and observed 50%
less white adipose mass compared to control WT (Wild Type) rats. Elevated levels of triglyceride
hydrolysis in adipocytes was observed. The longevity was inversely related to adiposity including
yeasts, flies, worms, fish, and rodents (Fontana L et al.,2007). This susceptibility of this model
was related to FAT10 overexpression, a ubiquitin-like protein that plays an unclear role in the
regulation of lipid metabolism (Blankenhorn EP et al.,2009). FAT10ko (FAT10 knockout) mice
have a low blood glucose level and insulin level compared to WT mice (Canaan A et al.,2013).
The researchers were interested about the effects of a high fat diet in FAT10ko mice and if a high
8

fat diet will result in low adiposity and low glucose and insulin concentration in their blood. They
found out that mice with the absence of FAT10 are not completely immune to becoming obese
while on a high fat diet. This is drawn from the fact that Fat10Ko mice on a high fat diet only had
a 16% decreased total adiposity while the lean FAT10 mice had a 50% decreased total adiposity
(Defuria J et al., 2011).

1.2 c. The rationale of the selection of the LEW.1WR1 rat for this thesis

The animal model for each selected for diabetes depends on what aspects of disease is being
studied. Furthermore, animal models play a vital role in the understanding of diabetes pathogenesis
and functional and genetic characterization (Arndt T et al., 2013). There are rat models that varied
from chemical ablation of beta cells to breeding rats that spontaneously develop autoimmune
diabetes. The animals used for type 1 diabetes are highly inbred (Phillips B et al., 2011). These
models include models of insulin resistance or models of beta-cell failure. On the other hand, T2D
models are obese, reflecting the human obesity of type 2 diabetes. Most of these models have
abnormalities of one or more genes causing glucose intolerance, insulin resistance, obesity leading
to a high blood glucose level. These malfunctions cause insulin resistance, hyperglycemia,
hyperlipidemia (Calcutt NA et al.,2009).

9

1.3 Other rodent models used in T1D

Figure 1. Summary of animal models of diabetes mellitus (Al-Awar A et al., 2016).

1.3.a NOD mice

Although almost all NOD mice of both sexes develop insulitis, only some of them develop overt
diabetes, suggesting that several factors modify the process from insulitis to beta-cell destruction
and the development of overt diabetes. NOD mice spontaneously develop hyperglycemia which
leads to autoimmune diabetes: infiltration of mononuclear cells into the pancreatic islet (insulitis)
is observed. Insulitis is not seen before three weeks of age but appears spontaneously at around
four weeks of age. The frequency of insulitis reaches 70%-90% by three weeks of age, and almost
mononuclear cells infiltrating the islets are mostly T cells (CD4+ and CD8+), but B cells, dendritic
cells, and macrophages are also observed. Despite massive infiltration of mononuclear cells into
the islets, beta-cells remain intact until 12-15 weeks of age, when destruction of beta-cells becomes
aggressive and overt diabetes develops. NOD females are known to have a higher burden of islet
infiltrates than males of the same
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age, causing earlier onset of diabetes. correlating with a previous onset of overt diabetes (Pozzilli
P et al.,1993).
After the onset overt diabetes, marked polyuria and polydipsia develop, and mice lose weight and
die within one to two months unless treated with a daily injection of insulin (Makino., et al. 1980),
as in in the case of human T1D.The main problem with NOD mice is sex bias when comes to
disease development
1.3.b LEW.1AR1 rat

In LEW is 1AR1-insulin-dependent diabetes mellitus (LEW.1AR1-iddm) rat, is a recessive model.
The genome-wide genome analysis using a (BN6LEW.1AR1-iddm) × LEW.1AR1-iddm] N2 (N2
BN) helped to discover three T1DM susceptibility loci in this rat model. Insulin-dependent
diabetes mellitus 8 (iddm8) was identified as a site of mutation for disease susceptibility recently
caused by the LEW.1AR1 strain (Weiss H. et al.,2008).
1.3.c Sprague-Dawley Rat

There is age dependent toxicity associated with STZ injection that makes the model unreliable and
sex bias when it comes to disease induction. But the high triglyceride and cholesterol levels in
blood, kidney damage, and dyslipidemia, common morbidities observed in rat model and diabetic
patients (Gangula P et al.,2007).
1.3.d BB rats

BB rats are derived from Canadian colony of outbred Wistar rats in which spontaneous
hyperglycemia and ketoacidosis occurred in 1970 (Mordes J et al.,2001) Affected animals were
the founders for two colonies later used to establish all other BB rat colonies. The colony in
11

Worcester, Massachusetts has been inbred, and the spontaneously diabetic are formally
“BBDP/Wor.” A second colony remains in Ottawa, Canada; the “BBdp”. Rats from this colony
are outbred.
The natural course of insulitis in the spontaneously diabetic BB rat is different from that of the
NOD mouse; in the rat, there is little or no persistent infiltration adjacent to the islets(“periinsulitis’) before progression to frank insulitis and overt diabetes. Insulitis in BB rats is
morphologically similar to that observed in human TID and features a predominance of Th1-type
lymphocytes (Hurbert K et al., 1996). After the onset of hyperglycemia, residual end-stage islets
with few or no inflammatory cells are observed. These are small and comprise predominantly nonbeta cells. Islet alpha, delta, and pancreatic polypeptide (PP) cell numbers and morphology appear
to be preserved. There is no published data on islets ghrelin cells in the rat. Unless treated with
insulin, hyperglycemic BB rats quickly develop fatal diabetic ketoacidosis. The working
hypothesis of autoimmune diabetes was initially derived from studies in the BB/Wor rat (Mordes
J et al.,1996). As depicted this hypothesis holds that diabetes in the rat results from an imbalance
between beta cell-cytotoxic effector cells and regulatory cells that generally prevent disease. The
hypothesis predicts the existence of at least two and perhaps three defects in all susceptible rat
strains. The first defect is genetic, involves the class IIµ allele of MHC, and leads to the generation
of autoreactive effector cells, not only in the BB rat but also in several other rat strains like
LEW.1WR1. The second defect leads to amplification of the autoreactive population or to
regulatory cells that generally prevent disease. The hypothesis predicts the existence of at least
two and perhaps three defects in all susceptible rat strains. The defect can be genetic or acquired.
In diabetes -prone BB rats, this defect is congenital lymphopenia, which can be overcome by the
transfusion of CD4+ ART2+ Treg cells. In the case of KDP (Komeda diabetes-prone) BB which
12

is a sub strain of BB rat (Haruhiko Y et al.,1997), a loss of function mutation in the cblb gene
appears to predispose to abnormal T-cell activation (Haruhiko Y et al., 2002). The KDP rat
combines an MHC -dependent genetic predisposition with a “disequilibrating” genetic defect
leading to autoreactive T cell activation.
The LEW.1AR1 (RT1-Aa , RT1-B/Du , and RT1-Cu ) and LEW.1WR1 (RT1-Au , RT1-B/Du ,
and RT1-Ca ) strains express also the MHC-II RT1-B/Du haplotype, and, conversely, the
original LEW (RT1-Al , RT1-B/Dl , and RT1-Cl ) strain cannot develop diabetes because of the
missing RT1-B/Du haplotype (Al-Awar A et al.,2016).
The rat model, LEW.1WR1 (LEW) rat which has heritable T1D susceptibility genes. This model
has a reproducible window of induction that can be studied in vivo. Various perturbations of the
immune system can efficiently induce type 1 diabetes up to 100% of animals. Perturbants include
regulated T-cell (Treg) depletion, innate immune activation with polyinosinic:polycytidylic acid
(poly I:C),infection with Kilham rat virus(KRV) or rat cytomegalovirus. LEW.1WR1 rats develop
diabetes at an increased rate (18%) after coxsackie B serotype 4(CVB4) infections, but only if
pretreated with a low dose of poly IC daily for three days.

1.3.e LEW/SsNHsd rats

LEW/SsNHsd (LEWIS) have LEWIS.RT1.L-L haplotype while LEW.1WR1 rats have LEW.RT1U1

U

1

Haplotype (Cort L et al., 2014). The LEW.1WR1 UBD promoter allele leads to higher inducible

levels of T1D. UBD-deficient rats show substantially reduced diabetes after viral infection.
LEWIS rats have low UBD mRNA expression and LEW.1WR1 rats have high UBD mRNA
expression (Cort L et al., 2014). The Lewis rat is sensitive to the development of several
autoimmune diseases, including adjuvant-induced arthritis (Brad B et al., 2011).
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Overall, LEW.1WR1 rats have susceptibility genes: UBD, RT1-N1, susceptibility loci: Iddm37,
Idm14.They have a low rate of spontaneous diabetes, not lymphopenic, both sexes are sensitive
to polyinosinic-polycytidylic acid (Poly IC) and/or virus induced T1D. So, we decided to use
LEW.1WR1 rats as our T1D rat model.
1.4 Metabolism in T1D
1.4. a Glucose and insulin homeostasis under normal conditions

There are two major types of diabetes, type 1 and type 2. People with type 1 diabetes cannot
produce insulin. People with type 2 diabetes can produce insulin, but they have reduced responses
to insulin. This thesis will focus on insulin regulation in type 1 diabetes.
Beta cells have a remarkable ability to store and secrete insulin with correct timing. Glucose is the
primary driver of insulin release. To sense the nutritional state, beta cells are clustered together in
islets (Schmitz O et al., 2008). Islets are connected through small blood vessels and receive ten
times more blood when compared to the exocrine regions near the islets. Normal blood glucose
levels range between 70-140 mg/dL. The glucose transporter 2 (GLUT2) in rodents
maintains blood glucose level, but notably GLUT1 in human

cells

cells facilitates glucose entry only.

The insulin secretion is regulated by K ATP dependent and K ATP independent pathways in
+

+

cells (Henquin J et al., 2011).
Oral ingestion of 75g of glucose can increase plasma insulin level by 20-30 pmol/L to 250-300
pmol/L within 30 minutes while the intake of the same amount of fat and protein can only increase
insulin level up to 50-60 pmol/L in a human body (Chang TW et al.,1978). β-cells constitutively
express GLUT2 which facilitates glucose diffusion. When glucose enters
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cells, glucose is

phosphorylated using glucokinase, which is a hexokinase. Glucokinase can be found in
mammalian cells, hepatic cells, beta cells, enterocytes and neurons (Suckale et al.,2008).
Glucokinase has a lower affinity to glucose compared to other hexokinases. Glucokinase is
inhibited by its product, glucose 6-phosphate. If glucose-6 -phosphate accumulates in the cell,
there is a feedback inhibition until cells consume all the glucose-6-phosphotases. Therefore,
glucokinase is considered as a rate-limiting factor in

-cell glucose metabolism (Jakob S et

al.,2008). The end point of glycolysis, pyruvate is converted to Acetyl-CoA and oxidized in the
TCA cycle in the mitochondria of beta cells to produce ATP. Glucose catabolism (glycolysis, TCA
cycle, and oxidative phosphorylation) are coupled with the K -ATP channel to regulate "ATP
+

sensitive potassium channel-dependent insulin release." Increases in the ATP/ADP ratio closes the
K -ATP channel and depolarizes the plasma membrane, causing the opening of voltage-dependent
+

Ca++ channels. The influx of Ca++ activates exocytosis of insulin-containing granules.
Insulin is initially in the form of proinsulin and stored in secretory granules. Proinsulin is converted
to insulin by removing C-peptides by signal peptidases. Insulin gets released on-demand in a
pulsatile flow. The synthesis of insulin is regulated at the transcriptional and translational level.
Pancreatic beta cells dysfunction plays a crucial role in type 1 diabetes as insulin secretion from
beta cells is a critical regulator in glucose metabolism in other tissues. The beta cells respond to
hormones like Gastrointestinal Insulinotropic Peptide (GIP), glucagon-like peptide (GLP-1)
(Baggio, L et al.,2007). Insulin directly suppresses the secretion of Glucagon as do Amylin which
co secreted with Insulin. But, GLP-1 inhibits the glucagon release from alpha cells (David S.et
al.,2014). When fasting blood glucose levels rise modestly higher, it can lead to severe
dysregulation of insulin secretion.
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1.4.b Stages of beta cell destruction

The progression of diabetes can be viewed as 5 definitive stages according to Gordon C et al.,2004.
These stages are characterized by beta cell mass, function, and phenotype. Stage 1 is the β cell
compensation stage. β cells secrete more insulin to increase blood insulin levels and maintain
normal blood glucose levels. The β cells are also infiltrated by macrophages and T cells. Stage 1
is characterized by hypersensitive glucose dependent insulin secretion and normal
At this stage,

cell mass.

cells are extraordinarily efficient at storing and secretion of insulin to maintain

normoglycemia. The stage 2- stable adaptation stage starts with high blood glucose levels. Glucose
dependent insulin secretion is decreased.

cell mass is decreasing. The beta cells can no longer

compensate so normal blood glucose level cannot be maintained.

cells are dedifferentiating at

this stage which is the loss of phenotypic beta cell response to increased blood glucose level. The
fasting blood glucose level is varying from 89-130mg/dL (5.5-6 mmol/l). The stage 2 cannot no
longer be considered as a compensated stage, because normal blood glucose level cannot be truly
maintained. Stage 3 is a transient stage hallmarked by rapidly rising blood glucose level. The
fasting blood glucose level rises from 130mg/dL-350mg/dL. Stage 4 is characterized by
decompensation and severe

cell

cell dedifferentiation. Blood glucose levels are typically above 350

mg/dL with severe insulitis. The rapid destruction of beta cells in type 1 diabetic patients can lead
to stage 5. The final stage, stage 5 is characterized by severe decompensation, severe beta cell
destruction and ketosis.
Plasma insulin levels are clearly a function of
development, deficiency of

cells health. In the early stages of type 1 diabetes

cell mass or function lead to changes in plasma insulin level. The
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deficiency of insulin in blood results in hyperglycemia and eventual diabetic ketoacidosis.
The role of

cells in humans during diabetic induction is not very clear. Scientific

advances have been restricted due to reduced access to human samples. Procedures that remove
pancreas sections are extremely harmful to patients as the pancreas controls several endocrine and
exocrine functions. The total output of insulin is totally dependent on the number of
cell mass) and the ability of each

cells (beta

cell to release insulin (function). Most information about

cell mass and function prior to stage 3 is currently from Non-Obese Diabetic (NOD) mice. But the
problem is,

cell mass loss of NOD mice models used in research experiments are vastly different

from humans. That is a one of the reasons to use the LEW.1WR1 rat model, showing similarities
in disease induction and progression to humans (discussed further in next section). There is limited
information about beta cell function and mass in prediabetic human patients.
There are other methods like measuring C-peptide, counting unmethylated INS DNA, glucose
tolerance test and first phase insulin response at an intravenous glucose stimulation test. Results
from these tests contribute to current knowledge about β cell function during disease onset in
humans. There is no glucose fluctuation until immediately before onset of diabetes due to the
body’s tight regulation of blood glucose levels (Srikanta S et al., 1984). But researchers have
observed losing first phase insulin release at 4-6 years before clinical onset of type 1 diabetes
(Keskinen P et al., 2002). The β cell mass was not changed during the time, however, the functional
impairment of beta cells during early on set is possible. When closer to hyperglycemia, decreased
first phase insulin secretion and increased C-peptide levels were observed (Sosenko J et al., 2006).
This might be due to dysfunction of β cells or death of βcells at onset of diabetes. Altogether,
dysfunction of β cells and losing β cells at a slow rate at the beginning will lead to rapid destruction
and functional abortion of β cells at later stages of progressing T1D, due to the activation of stress
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responses genes, proapoptotic genes, and NO like compounds (Chen C et al.,2017). In addition to
compromising ß cells function and survival, cytokines can recruit macrophages and T cells into
the islets, thus augmenting inflammation.
Viral infection is one of the causes of type 1 diabetes and it leads to β cell destruction. The islet
resident dendritic cells can interact with a β antigen and bind with receptors in dendritic cells.
These dendritic cells are caused to differentiate T-Helper cells (Th1) and activate B cells. The
helper cells, also called as CD4 + cells can activate other immune cells by releasing cytokines.
Th0 can secrete IL-2, IL-4 and interferon gamma (IFN-γ).
Those B cells can produce autoantibodies against β cells. Th1 can activate neutrophil,
macrophages, and start inflammatory reactions. Th1 can activate ROS dependent β cell destruction
by activating macrophages and neutrophil cells. Inflammatory cytokines like IL1B, TNFα,
IFN can activate NFκβ and STAT-1, which eventually decrease PDX1 and GLUT1 expression,
leading to reduced insulin production and secretion. The NFκβ induces endoplasmic reticulum
stress and β cell destruction. So, releasing cytokines from β cells can induce apoptosis (MariaLuisa et al., 2011).
Researchers observed that cytokines have significant impacts on beta cell populations due to direct
cell to cell contact which can increase

cell damage in prediabetic stage.(Skowera A et al., 2008),

(Brozzi F et al.,2015).Researchers have found that activation of NF-kB is a crucial step and causes
NO production, which leads to β cell destruction. IL-1β, IFN-γ, and TNF-α are cumulatively
enhancing the NO production by overexpressing NO synthase (Thomas HE et al.,2002).
Transgenic mice that are overexpressing the NO synthase (iNOS) developed type 1 diabetes in
their lifetime (Takamura T et al.,1998). And knockout iNOS mice did not develop type1 diabetes,
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and

cells were protected (Flodstrom M et al.,1999). The INOS overexpressed cells can produce

a large amount of NO, which can downregulate the transcription factors like PDX-1 and Isl-1,
eventually leading to regulate β-cell dedifferentiation. The cytokine-dependent NF-kB can
upregulate the production of monocyte chemoattractant protein-1 (MCP-1) (Chen MC et al.,2001).
The downregulated SERCA-2b (sarco endoplasmic reticulum Ca2+ ATPase type 2b) causes
severe stress to the endoplasmic reticulum, leading to apoptosis of

cells (Cardozo AK et

al.,2001). A member of MAPK (mitogen-activated protein kinase, c-Jun NH2-terminal kinase
(JNK) is activated by IL-1β causing beta-cell apoptosis (Ferdaoussi M et al.,2008). IFN-γ also
cumulatively participates with IL-1β in this process (Eizirik DL et al.,2001).
The classically characterized T1D is the presence of antibodies and T-cells, which are reacting
with islet antigens at new-onset adult (>16 years old) type 1 diabetic patients (Roberto M et al.,
2007). Giving drugs that can suppress immune activity can slow down the β-cell apoptosis process,
and histology analysis of pancreases shows that immunological activity in islets. T lymphocytes
are considered as a primary mediator for T1D. Notably, the drugs against T lymphocytes have
delayed the T1D progression (Roep BO et al.,2003). CD4+ and CD8+ are two types of T
lymphocytes that are involved in T1D and the role of these two types of cells is controversial. It is
suggested that CD4+ T cells contribute to proper homing and CD+8 T cells as effector cells
(Thivolet C et al.,1991). CD4+ T lymphocytes are considered as T helper cells (Th0), and after
encountering antibodies, they secrete IL-2, INF-γ, and TNF-α and Th2 cells secrete IL-4, IL-5, IL10 and IL-13. Th1 cells can destroy beta cells by secreting INF-γ. Th2 cells are also causing β-cell
apoptosis through IL-10 (Heitmeier MR et al.,1997). Activated T cells and macrophages release
several inflammatory cytokines like interferon-γ (IFN-γ), interleukin-1β (IL-1β) and tumor
necrosis factor-α (TNF-α), which cause β-cell destruction (Thomas H et al.,2002). Pro19

inflammatory cytokines like interleukin-1beta (IL-1β) and gamma-interferon (γ-IFN) can activate
signaling pathways, causing dysfunction of β-cells (Jason C et al.,2011). In vitro culture showed
that cumulative effects of IL-1β or IL-1β+IFN- γ could cause β-cell destruction similar to what
they observed in prediabetic patients (Hostens K et al.,1999).
Leptin has an anti-apoptotic effect on

cells that eventually reduce triglyceride accumulation in

the liver. Leptin level typically increases with inflammation and infection. Moreover, exposure to
external or internal stimuli like IL-1, TNF-a and LPS increases the circulating of leptin and leptin
expression in adipose tissue. (Noriko I et al 2008). According to Morika et al.,2007, mice with a
disrupted leptin receptor had severe glucose intolerance and low insulin secretion from beta cells.
All these findings suggest that leptin has a protective effect on

cells. Resistin is usually

expressed in mice and macrophages in humans (Tomaru T et al., 2009). An increased resistin level
is associated with insulin resistance in humans and rodents. (Brown E et al.,2007).
1.4.c How beta cells impact metabolic tissues and hormones

Insulin is produced and secreted in pancreatic ß cells, which are responsible for glucose influx. By
suppressing the glucose production in the liver and stimulating glucose uptake in muscle and fat,
insulin reduces blood glucose level. Skeletal muscle accounts for 60-70% of whole-body insulin
stimulated glucose uptake. Insulin regulates muscle metabolism by promoting glucose uptake,
glycogen synthesis and lipid utilization and storage. Insulin stimulates glucose uptake in skeletal
muscle by translocating GLUT4 (Jingjing Z.et al.,2014). Insulin action in the liver leads to
reduction of glycogen breakdown, glucose synthesis, increased glycogen production and enhanced
lipid and glycogen storage. GLUT2 is expressed in the liver, in renal and intestinal absorptive cells
unlike GLUT4, which primarily expresses in muscle and fat cells.
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When there is an increase in blood glucose, pancreatic beta cells release insulin. Insulin binds with
the insulin receptors and activates the tyrosine kinase domain initiating a cascade of signals. The
cell signaling molecules like IRS, P13K, PDK1, AKT andAS160 are activated and eventually lead
to cell survival and proliferation. The GLUT4 translocation is initiated by activating 1RS/ phosphatidylinositol (PI)-3 pathway. GLUT4 translocates from cytoplasm to cell membrane. Once
GLUT4 transporters are open, cells can uptake glucose. Glucose will be used in several ways in
cells. Glucose can make ATP and pyruvate through glycolysis. Pyruvate can convert to lipids
through lipogenesis. Glucose can store as glycogen through glycogenesis. If cells cannot uptake
glucose, all these processes will be affected. Without insulin, glucose cannot be up taken by cells
and cells are starved from energy (Jennifer J et al., 2001)
1.4.c.1 Muscles

The lack of insulin in T1D causes poor protein, lipid and glucose metabolism. So, this may
eventually cause both acute and chronic biochemical and anatomical problems in skeletal muscles.
The muscle cramping is one of the common symptoms with Diabetes Mellitus. It can result from
electrolyte imbalance, hypoglycemia, or neuropathies. Muscle fraction is rare and only seen in
poorly controlled diabetic patients. Other than that, researchers observed contractile weaknesses,
decreased oxidative activity, reduced muscle mass, muscle mitochondrial dysfunction and insulin
resistance in T1D patients. With T1D,

cells destroy and reduce insulin signaling. Therefore,

reduced amounts of insulin receptors decrease the activity of P13K. This may eventually cause
impaired GLUT4 translocations in skeletal muscles. Animals and human models of T1D show
changes in downstream signaling cascades, including/ protein metabolism, fatty acid utilization,
cellular stress responses, glycolysis and nucleotide metabolism in skeletal muscles (Ohlendieck K
et al., 2012).
21

1.4.c.2 Liver

The liver plays an important role in glucose metabolism because it stores glycogen and produces
glucose through glycogenesis and gluconeogenesis. There are several hormones and cytokines that
act on glucose homeostasis in the liver. Thirty to sixty percent of glucose uptake by the digestive
tract, undergoes hepatic metabolism through storing glycogen and converting them in to amino
acids or fatty acids. Normal blood glucose levels are maintained by insulin which simulates
glucose uptake by adipose tissues and skeletal muscles and inhibits hepatic release of glucose.
When beta cells are not properly functioning, glucose uptake is reduced by adipose tissues and
skeletal muscles and decreased inhibition of hepatic glucose output (Chi Zhang et al.,2012).
According to Bernarf T et al., 1990, the expression of liver/beta glucose transporter in
hyperglycemic rats have reduced but in the liver, expression of same transporter is minimally
changed over the experiment period .Not only that, hyperglycemia causes the liver to dysfunction
and hepatic cell death via oxidative stress in T1D through Bcl2 proteins that act on mitochondria.
Signals from mitochondria cause mitochondria dependent cell death in liver (Prasenjit M. et al.,
2010).
1.5. What is known about the metabolic phenotype of the LEW.1WR1 rat
There are very few studies that have been done related to metabolic changes of 1WR1 rats. The
1WR1 rats have genetic predisposition to autoimmune destruction of beta cells and collageninduced arthritis with high incidence in both genders. LEW.1WR1 rats also develop more severe
and more human-like complications of diabetes when compared to other models such as NOD
mice and Sprague Dawley like induced diabetes models.
These rat models can show insulitis even without Poly IC induction. According to John P. study,
among the non-diabetic pancreases, 24 showed no pathology, but one male rat with +1 insulitis
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and one female with +3 insulitis (low insulitis is+1 and high insulitis is +4). To quantify insulitis,
pancreases were harvested and fixed in 10% formalin and scored by light microscopy on a scale
of 0 to 4. But only 2% of 72 total rats developed diabetes spontaneously.
The diabetic symptoms of 1WR1 rats are weight loss, increased water consumption, urinary
ketones and glycosuria. When animals were treated with insulin, they showed rapid improvement,
such as, low blood glucose level, resolution of ketonuria and weight gain. The histology analysis
of diabetic 1WR1 rats showed distorted small size islets and infiltration of lymphocyte (Mordes J
et al., 2005). LEW.1WR1rats are not lymphopenic. There was no evidence showing severe loss
of CD4+ (T helper cells), CD8+ (Cytotoxic killer cells), or ART2+ cells, which is a characteristic
of autoimmune diabetes in BBDR rats. They have normal immunophenotypes, but in barrier
housing, only a small percentage produce ketosis prone diabetes mellitus on a consistent basis.
Immunochemistry has confirmed that insulin containing cells are largely missing in both acute and
chronic diabetic rats. These rats are susceptible to collagen induced arthritis. Rheumatoid arthritis
is common in type 1 diabetic families (Mordes J et al., 2010). Elevated TCR-Cβ transcripts levels
were observed 7- 9 days after poly IC induction and a similar pattern was observed with insulin
transcripts at the same time. Dr. Love-Rutledge has seen high blood insulin levels in
LEW.1WR1rats (Unpublished data).
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Figure 1.Blood insulin levels in LEW.1WR1rats.Blood insulin level was measured 0 hours
,16+hours,48+ hours after PIC induction. Wista Furth rats were used as control rats.(Dr.Sharifa
Love-Rutledge,Unpublished data)

LEW.1WR1rats are carrying RT1u haplotype as BB rats (even though BB rats are lymphopenic)
which makes them susceptible to develop T1D. Increased insulin in control rats suggests that this
may not be the case, but that there is some other underlying metabolic aberration occurring in
1WR1 rats. When these animals are backcrossed with parental resistant strains with a different
haplotype, the susceptibility is reduced to 25% (Cort L et al., 2014). RT1l is a diabetes resistant
haplotype and RT1u is a diabetes susceptible haplotype. In a study of Wistar rats bred to have the
RT1a and RT1u haplotype, Wistar Ottawa Karlsburg W (WOKW) rats developed impaired
glucose tolerance and were hyper insulinemic but did not develop diabetes. So, the WOKW rat
model is characterized with insulin resistance, hyperinsulinemia, obesity, impaired glucose
tolerance, dyslipidemia, and hypertension. This rat group showed metabolic syndrome. WOKW
rats are significantly heavier than control rat groups and both sexes showed similar tendencies
toward body weights and BMI. Insulin level is significantly higher at the age of 10 weeks and
serum triglyceride levels are significantly high in all age groups. Furthermore, serum cholesterol
and LDL levels are low in both sexes of WOKW rats compared to controlled rat groups. These
rats have a significantly higher adipose index number which determines obesity status. This shared
haplotype suggests that there is an underlying metabolic mechanism that plays a role in developing
type 1 diabetes in the 1WR1 rat. It is sometimes difficult to distinguish between T2D, T1D and
metabolic syndrome susceptibility which depend on the different yet sometimes overlapping
genetic backgrounds with a specific mixture of metabolic predispositions (Jens van den Brandt et
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al.,2000). It has not been proven that the WOKW rat overexpresses UBD, an identified
susceptibility gene found within the RT1u haplotype in the 1WR1 rat. However, this gene has been
shown to have an impact on the metabolism of rodents.
1.5.a Lipid metabolism

UBD promotes adiposity, insulin resistance, and inflammation, and reduces fat oxidation,
uncoupling, and AMPK activation in skeletal muscle. UBD deletion can expand lifespan of mice
through increased phosphorylation of lipid droplets and reduced adipose mass, beta oxidation and
mitochondrial respiration. When UBD was knocked out in mice, they had enhanced fatty acid
oxidation, upregulation of lipid metabolism genes, and appeared leaner (Allon et al., 2012). Insulin
inhibits breakdown of fat in adipose tissue by inhibiting the intracellular lipase that hydrolyzes
triglycerides to release fatty acids. Decreased adiposity with UBD knockout reflects the
contribution of over expressed UBD gene in lipid synthesis and lipolysis in diabetic induction.
The gene encoding Lipe (HSL) and PNPLA2 (ATGL) are major lipase genes in adipocytes,
upregulated in UBD/FAT 10 knockout mice. And also, UBD knockout mice have significantly
higher expression of fatty acid breakdown related genes (ACOX, ACOT1, ACOT3, PPARα).
Lipolysis is associated with ß-oxidation and recycling of triglycerides. So, genes indirectly related
with ß oxidation and triglyceride synthesis are upregulated. This data suggests increasing lipolysis
in UBD knockout genes. So, we expect to observe UBD over expressed LEW.1WR1 rats that have
altered lipid metabolism compared to our controlled rat group.
The LEW.1WR1 rats become diabetic 12 days after Poly IC injection. They start losing the ability
to maintain their blood glucose level. Poly IC treated rats have increased membrane lipids and
ceramides in rat islets due to ER stress (Nandan K et al., 2018).
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1.5.b. Glucose metabolism

Insulin promotes glucose uptake and fatty acids uptake in adipocytes. Insulin tolerance tests were
performed after 6 hours of starving in UBD knockout mice. The study has shown KO mice on
normal diet have changes in body composition, energy usage and tissue metabolism. Those rats
have reduced circulating insulin and glucose in metabolic tissues (Allon C et al., 2014).
LEW.1WR1 rats have a high blood glucose level and reduced insulin sensitivity with T1D. Wistar
Ottawa Karlsburg W rat strain shows hyperinsulinemia, obesity, insulin resistance and glucose
tolerance (Amaya A.et al.,2009). Karlsburg W rats were at age 4, 6, 8, 10, 12, and 14 weeks and
LEW.1WR1 rats we used for the study were 18 days old. So, LEW.1WR1rats are younger in age
and may have changes indicative of the early stages of WOKW metabolic dysfunction.

It is crucial to know exactly the typical features of the metabolic abnormalities in order to
differentiate specific categories of metabolic phenotypes associated with T1D. These data suggest
that phenotypic differences we observed with T1D induction are not completely driven by the
immune response.
According to this data, there should be an underlying mechanism to develop T1D diabetes in
1WR1 rats other than directed by immune responses. Although the 1WR1 rat model that is
commonly used in T1D studies is virus induced LEW.1WR1 rats, they can develop T1D
spontaneously and the underlying metabolic mechanism has a role to play which was not clearly
addressed before. We hypothesize that overexpressed UBD gene may alter the lipid, glucose and
insulin mechanism which increases the susceptibility to spontaneously T1D. Identifying the
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profound metabolic changes that occur in this population of people with T1D susceptibility can be
used as potent biomarkers in future for early diagnoses.
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Chapter 2
Methodology
Chemicals
10mL of endotoxin-free physiological water was added to 10mg of Polynosinic:polycytidylic acid
(poly(I:C)) (HMW) Vacci grade InvoGen and made 1mg/mL Poly(I:C) Invivogen (San Diego,
CA). In Vaccine Grade vial. Mixed the solution by pipetting up and down. The mixture was heated
for 10 minutes at 65 - 70°C. Allowed to cool for 1 hour at room temperature to ensure proper
annealing. All steps should be done under a biological safety cabinet to maintain sterility. Poly IC
at a concentration of 1mg/ml stored at -20 (add units) until use. 10 mL of (PBS (10X), pH 7.4
(Gibco™)) were mixed with 9mL with Distilled water to make 1X PBS. 1x Phosphate Buffer
Saline (PBS) from Thermo Fisher Scientific (Waltham, MA) was used for control rats and Poly
IC dilutions prior to injecting treated rats.
Animals
LEW/SsNHsd (SsNHsd) and LEW.1WR1 (1WR1) (Envigo (Indianapolis, IN) and Biomere
(Worcester, MA) rats were nearly 21-24 days old when we obtained them. At the beginning of
study rats were 28 days old. Rats kept in UAH Vivarium were maintained with a 12-hour lightdark cycle, and protocols approved by UAH IACUC. Four rats kept in one cage, and distilled water
and (invigo++ 18% protein rodent diet) supplied ad libitum. Rats of each strain were randomly
separated into two groups, control and treated, 1WR1-Control, 1WR1-treated, SsNHsd -Control,
and SsNHsd -Treated.
Poly IC injection
The body masses were measured before injection during the induction period. 1μg/g body mass
Poly IC was injected to treated rats and with the corresponding volumes of PBS injected into
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control rats, instead. Injections in the treated and control rats occurred every other day for six days.
The rats were 4 weeks old at the time of harvesting.
Terminal blood glucose level measurement
The terminal fasting blood glucose level was measured after 6 and a half hours of fasting in rat
metabolic cages. The terminal fasting blood glucose level was measured using Alpha Tracks 2
meter by Zeotis (Parsippany.NJ). Rats were anesthetized using isoflurane; the tail wiped with
ethanol, and the dorsal vein was pricked using a 25G needle. We discarded the first blood drop.
Figure 3. Islet Size Comparison. This figure shows the representative images of insulin-stained

islets at sizes extra-small (<10 mm), small (10-15 mm), medium (16-20 mm), and large (>20 mm).
Magnification was at 2 x 500 μ.
Histology
Rats were anesthetized and exsanguinated by cardiac puncture. The pancreas was carefully
dissected out without disrupting the integrity of the organ — the organs were placed inside a
cassette. The cassettes were put into a beaker of 10% neutral buffered formalin (Fisher Scientific)
to fix for approximately 24 hours at room temperature. After fixing, the organ was placed in 70%
Ethanol (Thermo Scientific™) inside and mailed to Histowiz (Brooklyn, New York) for paraffin
embedding, sectioning, staining, and digitizing of slides. The volume of fixative must be 20x over
the sample volume, and the tissue must be immersed in the solution. The samples were sectioned
(4 μm) and stained against CD68 (Monocytes and Macrophages, Dendritic cells), CD3 (T cells),
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and insulin (beta cells). Insulin staining was done to determine the relative size of each islet. The
digitized slides were scored based on appearance by Blinded scorers. Undergraduate scorers were
recruited to score total islets on each slide and separated them according to size differences,
Extra small, small, Medium, Large islets. The level of intensity of the CD3+ and CD68+ also
scored in 10 representative islets in each slide. Islets scored on a scale from 1-4, and 1 indicates
low infiltration, and 4 indicates the highest infiltration. The darker CD3+ stain indicates a higher
number of T cells. The size chart used to score the size of each islet is depicted in Figure 4.
Quantitative Polymerase Chain Reaction

Approximately 0.15g piece of liver was placed into a 1.5mL centrifuge tube and weighed.
Immediately add 1 mL of TriZOL was added to the tube, flash frozen in liquid nitrogen and stored
at -80C until processed. On the day of processing, liver sample is transferred onto a piece of folded
aluminum foil, flash-frozen in liquid nitrogen, crushed with a pestle and transferred into (VBottom ScrewTop Tube 500 µL matrix tube (Thermo Fisher Scientific). 1mL of TriZOL was
transferred into matrix tubes. The samples were homogenized with Super FastPrep-2 (Thermo
Fisher Scientific) at 6 settings for 40 seconds then immediately placed on ice for 5 minutes.
Supernatant was removed and placed into the original centrifuge tube. We then added 0.2mL of
chloroform to the tube vortex for 15 seconds and then incubated for 2 minutes at room temperature.
The tube was centrifuged for 15 minutes at 12,100 x G and 4ºC Upon completion, the upper phase
transferred to a new 1.5mL tube 0.5 mL of isopropanol added to precipitate the mRNA. This
solution was vortexed at speed 8 for 5 seconds and then incubated at room temperature for 10
minutes. The centrifuge tube was then spun at 12,100 x G at 4ºC for 10 min to pellet the RNA.
The liquid was carefully removed, leaving behind only the white pellet. The pellet was washed
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with 75% ethanol, vortexed, and centrifuged to remove the supernatant. The pellet was air dried
using a Savant Vac with low temperature for 5 minutes to remove the traces of ethanol. The dried
sample was dissolved with 25 microliters of Nuclease free water and placed in a 55ºC heat block
to rehydrate for 10 minutes. The sample was cooled immediately by placing on ice for 15 secs.
Then the quantity and quality of RNA was measured using Thermo Scientific™ NanoDrop™ One
Microvolume UV-Vis Spectrophotometer. The ratio of absorbance at 260 nm and 280 nm was
used to assess the purity of DNA and RNA. The ratio of ~2.0 generally accepted as “pure” for
RNA. If the ratio is appreciably lower in either case, it may indicate the presence of protein, phenol,
or other contaminants that absorb strongly at or near 280 nm. We stored the samples at -80 C until
cDNA conversion.
cDNA amplification

The 2X reverse Transcriptase Master Mix was Prepared from the High Capacity cDNA Reverse
Transcriptase Kit from Applied Biosystems following the manufacturer’s instructions.
Preparing the cDNA RT reactions: Nucleic Acid (ng/uL) of each sample was known. Since it’s
too concentrated (above 5000), samples diluted by a 1:100 ratio using nuclease-free water. The
value you obtained was divided by 500 and found the volume of RNA needed for 50µl reaction
volume. The rest of it is nuclease-free water.
Each cap was Labeled of a MicroAmp 8-Tube strip 0.1mL with the sample number. Pipetted the
calculated volume of nuclease-free water and mRNA into the designated well. Next pipetted the
correct amount of 2XRTmaster mix into each tube close it, and the final volume of each tube
should be 50 microliters.
Performed reverse transcription in SimpliAmp Thermal Cycler:
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Program conditions for each step as follows:
a. Step 1: 25 C for 10 minutes
b. Step 2: 37 C for 120 minutes
c. Step 3: 85 C for 5 minutes
d. Step 4: 4 C for infinity
Place the tubes in a thermal cycler securely and start the run. Once the run finished samples were
stored at 4̊ C.
Preparation of Primers

The NCBI Primer Blast tool was used and selected the gene of interest from the drop-down list.
Typed the gene wanted to make primer and searched for that for Rattus norvegicus”.Then from all
the hits mRNA sequence for the selected gene should be selected. cDNA was selected without
introns. To make PCR primers, we need the whole sequence. The NCBI Primer Blast was selected.
The mRNA sequence or accession number of gene interest was copied to the primer window. So
you can change the size of primers, Melting temperature. Minimum and Maximum temperature
should be selected 2 degrees around optimum temperature. The organism should always be
``Rattus norvegicus”. Then clicked the primer blast button. The software runs for a few minutes
and shows a graphical presentation of primers and where it binds to genes. Scrolled down and each
primer pair shown with the length of primer, melting temperature, GC% content. The primers were
selected by specificity and checked whether they can bind to another site of gene. Then the selected
primer sequences were sent to Invitrogen to make DNA oligos, primers for PCR. The first primer
set was selected and sent to Invitrogen to create primers. The primers were centrifuged to ensure
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all the DNA at the bottom of the tube before opening. In the tube, there is nmol amount primer
shown. For example, if a forward primer has a 320nmol amount and added 320 µL of RNAse
water. water was added to make a 100 µM solution. 10 µL aliquot was taken and added to 90 µL
of nuclease-free water to prepare a 10µM solution for qPCR analysis.
The primer pairs we used for analysis were followed.
Table 1. Table of Primer

Gene

Forward 5’-3’

Reverse 5’-3’

RPL32

AAACTGGCGGAAACCCAGAG

GCAATCTCAGCACAGTAAGATT

ATGL

CGGCATTTCAGACAACTTGCCACT GCAGGTTGAATTGGATGCTGGTGT

SCD-1

ACATTCAATCTCGGGAGAACA

Name

CCATGCAGTCGATGAAGAAC

DGAT-2 CGCCCTCTTCATCTGGTTTAT

GCTCACAGCCTCTCTGATTT

DGAT-1 GTAAGTGGTGAGTGGGTGTATG

GGCTTCATGGAGTTCTGGATAG

GLUT-2

GGTGAGTGGGTGCTCATAAA

CACCAGTCACTTCTGGGTAAA

SREBP-

GAGACTGGAGACAGGGTAAATG

GCCTCAATCTGACCTCCTTATC

1c
ChREBP GGGACAGCCATCAGCTATTT

GGTCTCACAAGCTCCAGTATTT

P53

CCCTCTTTACCCTACCCTATCT

GGAGCTGAAGCTCTGGTTATAG

UBD

CTTTTCTCACTCGGCCTCTG

GAGACCTTGGTTTGGGACCT

ACSL-1

CAAGGTGCTTCAGCCTACCA

ATCCAACAGCCATCGCTTCA

PCK-1

GTCCCCCTTGTCTACGAAGC

GGCCTCTGATCTCATGGCAG
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G6PC

GTGGGCAATTGTTTGCTGGT

GACTCTCCCCTTGCCGTTTT

PFKB3

CCACCAAAAAGCCTCGCATC

TCCCTAGCAAAGGTTGTCCG

PNPLA2 GCCACAGTACACAGGGATAAA

GAGTTTCGGATGGAGAGAATGT

CPT-1

CCACGAAGCCCTCAAACAGA

CACACCCACCACCACGATAA

IFN-b

ACTACAAGCAGCTCCAGTTC

TGAGGTTGAGCCTTCCATTC

Table 2. Power Up Sybr green Master mix

PowerUpTM SYBRTM Green Master Mix (2X) 10 μL
Forward Primers (use 300–800 nM)

1 μL

Reverse Primers (use 300–800 nM)

1 μL

Nuclease-Free Water

7 μL

Total

19 μL

The PowerUp Sybr Green Master Mix (Applied BioSystems) was used for a 20 µM total volume
reaction. The reactions were prepared according to the manufacturer protocol Scale, the
components according to the number of reactions, and included 10% overage.
Components of the sybr green mix were mixed thoroughly, then centrifuged briefly to spin down
all the content and eliminate any air bubbles. The 19 µL of total volume added to each well and
1µL of DNA template from each sample was added separately to each well to reduce pipetting
error. There were 3 replicates per each sample. In the end, a total volume of 20µL was transferred
to each reaction well of the optical plate. The plate was sealed and covered with an optical adhesive
cover. The plate was centrifuged for 1 min at 1000 rpm (112 G) to remove any air bubbles — the
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reaction plate placed in the Quant Studio (™) 3 Real Time qPCR was performed on the reaction
plate using the following cycling model.
Table 3. Standard cycling mode (primer Tm <60°C)

Step
UDG activation
Dual-LockTM DNA
Polymerase
Denature
Anneal
Extend

Temperature Duration
50°C
2 minutes
95°C
2 minutes

Cycles
Hold
Hold

95°C
55–60°C
72°C

40

15 seconds
15 seconds
1 minute

Table 4. Dissociation curve conditions were listed below.
Ste
p
1
2
3

Ramp rate

Temperature Time

1.6°C/second 95°C
1.6°C/second 60°C
0.15°C/second 95°C

15 seconds
1 minute
15 seconds

The Quant Studio 3 instrument was set to perform above steps. The non-specific amplifications
were checked using a dissociation curve.
Upon completion of qPCR, relative gene expression was calculated using the ΔΔ Ct method, which
relates the PCR signal of the target transcript in a treatment group to that of another sample such
as an untreated control. The 2(-ΔΔCt) method is a convenient way to analyze the relative changes in
gene expression from real-time quantitative PCR experiments.
Gene expression was normalized to the RPL32 gene, the LEW/SsNHsd Control group as the
calibrator or untreated control. Samples were run with RNAse free water instead of template DNA
to see if there any impurities that give signals. Each sample Ct mean was calculated, and standard
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deviations calculated for each mean Ct value. Each sample run in triplicate and data was
normalized to RPL32 and control LEW/SsNHsd group When you evaluate fold change; the
unequal PCR efficiencies decrease in the accuracy of the calculated fold change. Those samples
were repeated to improve standard deviations. Mean Ct values and standard deviations used in the
ΔΔCt calculations to test to compare intergroup differences.
Terminal blood sampling and analysis
Blood collected in a 15 ml conical tube and 4mL heparinized vacutainer. Nearly 10mL of blood
from heart puncture was taken and marked rat number and date. The conical tube samples time
was recorded, and the blood clotted on a rack for 15 minutes exactly, and then centrifuged for 10
minutes 1000xg at 4ºC. Samples were removed and serum was separated from red blood cells with
a micropipette and put in pre-labeled Eppendorf tubes. The rat plasma separated by centrifuge the
blood at 1000 x g for 10 in at 4°C and stored in -80 ̊C.Serum samples were used for Insulin assay,
Triglyceride, Cholesterol, metabolomics, cytokine, and chemokine assays.
Chemokine and cytokine multiplex array.
Serum samples were prepared and sent to eve technologies, Eppendorf were labeled as L1, L2,
and L3.L1 for Metabolic Array, R1 for Chemokine array. The 0.5 – 0.65mL snap-cap
microcentrifuge tubes used for the metabolic and chemokine array as preferred by Eve
Technologies. 0.1 µl of aliquot for metabolic panel and chemokines were prepared as follows. For
the Metabolic array, 1µL of DPP-IV (Thermo Scientific) 1µL of aprotinin inhibitors (Thermo
Scientific) was directly added to 50µL of serum. This was mixed and added to the final safeloc
Eppendorf tube.

For Chemokine array, two-fold dilution was done by adding 1X PBS (PBS

((10X), pH 7.4 (Gibco™)), 100µL of PBS was added to 100µLof serum for chemokine array then
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80 µL were transferred to a labeled safe lock Eppendorf tube and temporarily frozen in -20ºC.
Samples were moved to and stored in -80 degrees until processing. The metabolic hormone,
cytokines, and cytokines level were measured by Eve Technologies Calgary, Canada. Blood
hormone and cytokine levels are analyzed using Rat Hormone 10-Plex Discovery assay and Rat
Cytokines 27-plex Discovery assay (Eve Technology, Canada). Results of the following
biomarkers were given., Eotaxin, G-CSF, GM-CSF, IFN gamma, IL-1alpha, IL-1beta, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, KC,
LIF, LIX, MCP-1, M-CSF, MIG, MIP-1alpha, MIP-1beta, MIP-2, RANTES, TNF alpha,
LIX.One-way ANOVA followed by Turkey multiple comparison tests were performed using
GraphPad Prism 7.04 (La Jolla, CA) to compare each rat strain and treatment group. Mean,
Standard deviation, and the number of samples for each group used to calculate and see the
difference is significant (p <0.005) for each gene measured.
Enzyme-Linked Immuno Sorbent Assay
Mercordia Ultrasensitive Rat Insulin ELISA kit used and 96 well plate was used, and each sample
and calibrators have duplicates. Duplicating allows you to calculate and assess inter-assay
variability, or the reproducibility of results. All reagents and samples must be brought to room
temperature before starting the experiment. A calibration curve prepared for every assay. Enzyme
conjugate 1 X solution and samples and wash buffer prepared. The buffer solution was made by
adding 1000ml distilled water. 25 µl each of calibrators, samples, controls, pipetted out for each
well. 100µl of enzyme conjugate 1x solution into each well. The plate incubated on a plate shaker
(Corning-LSE) for 2 hours at room temperature. The plate was washed 6 times with 700 µl of 1X
wash buffer solution per and discarded the reaction volume by inverting the microplate by over a
sink. Nearly 350 µL of wash buffer was added to each right tap firmly several times to remove any
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excess liquid and repeated 5 times. Then 200µl of substrate TMB was added to each well and
incubated for 15 minutes at room temperature, then 50µl of stop solution was added. The plate has
been placed on a shaker for nearly 5 seconds for mixing. The optical density measured at 450nm,
and results were calculated using GraphPad Prism 7.04 (La Jolla, CA).
Triglyceride Assay
Triglyceride Colorimetric Assay (Cayman. 10010303) was done using rat liver samples and
plasma samples. Plasma samples were an aliquot from the previously described preparation.
Liver preparation
Approximately 320 mg of liver samples were used for the assay. The liver samples were
homogenized using Homogenizer Super FastPrep-2 (Thermo Fisher Scientific).in 2 ml of the
diluted NP40 Substitute Assay Reagent samples were centrifuged at 10,000 x g for 10 minutes at
4° C. Once it ends transfer the entire supernatant into another tube and stored at -80 ºC. The
supernatant used for the assay. 1:10 ratio diluted with NP40 Substitute Assay Reagent used for the
assay.
10 μl of each standard added to the designated wells on the plate. 10 μl of each sample in duplicate
added to each designated well. 150 μl of enzyme mixture added to each well. The plate was covered
using Parafilm and shaken for a few seconds using a shaker (Fisher Scientific), then incubated for
15 minutes at room temperature. The absorbance was measured at 530-550 nm using a plate reader
(Molecular Devices, Spectra Max).
Cholesterol Assay
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Cholesterol Fluorometric Assay (Cayman 10007640)- was done using serum. The standard was
made up of 10 mM cholesterol (5-Golestan-3β-ol in ethanol. The reagent is ready to use for the
preparation of the diluted cholesterol standards. 50µL of sample is serum used for each well, and
2 replicates were taken for each sample to obtain reproducible results. The first two rows allocated
for duplicates of standards 20 μl of cholesterol assay standard (Item No. 10008053) diluted with
980 μl of diluted assay buffer. The eight clean glass test tubes were taken and mark them A-H.
The amount of cholesterol standard and assay buffer to each tube was added, as described in the
table below.
Table 5. Amount of cholesterol standard and assay buffer
Tube
A
B
C
D
E
F
G
H

200 μM Cholesterol
Standard(μl)
0
10
20
30
40
60
80
100

Assay Buffer(μl) Final Concentration
10000
990
980
970
960
940
920
900

(μM cholesterol)
0
2
4
6
8
12
16
20

The assay cocktail was prepared using assay buffer (4.745 ml), cholesterol detector (150 μl), HRP
(50 μl), cholesterol oxidase (50 μl), and cholesterol esterase (5 μl) Covered the plate with the plate
cover provided. The plate allowed to sit for 30 min at 37°C in an incubator (Fisher Scientific) and
measured the fluorescence of excitation wavelength at 530nm,535 nm, and 540nm.
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Statistical Analysis
For qPCR analysis,Triglycerides and cholesterol assays if the Standard deviation of triplicates
standard deviation above 0.25 sample replicates neglected. One-way ANOVA followed by Turkey
multiple comparison tests performed using GraphPad Prism 7.04 (La Jolla, CA) to compare each
rat strain and treatment group. Mean, Standard deviation, and the number of samples for each
group used to calculate and see the difference is significant (p <0.005) for each gene measured.

Results
The masses of each rat measured during the experiment period. During 6 days of the experiment
period, we didn’t observe any significant variation of bodyweight of our LEW.1WR1 rats that
were kept only for 6 days. We have observed increasing body weights of all rat groups with time.

Figure 4. Body mass changes over the induction period.
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No differences in body mass during the treatment period. Data are expressed as the mean with
SD, n=8 in LEW/SsNHsd control, LEW/SsNHsd treated, LEW.1WR1Control, and
LEW.1WR1treated rat groups.
Although there are no differences in mass, control LEW.1WR1 rats have higher terminal fasting
blood glucose levels compared to LEW/SsNHsd rats (Figure 2). At this time point, the rats were
not hyperglycemic but LEW.1WR1 rats had blood glucose level nearing 150mg/dL. If those rats
were hyperglycemic, they would have more than 200mg/dL (Pournaghi P et al.,2012.).

Figure 5. Terminal blood glucose level of four different rat groups.
One-way ANOVA was performed. Different letters represent significant differences between each
group. Similar letters represent that groups are not significantly different to each other. Terminal
blood glucose level was measured in mg/dL. LEW.1WR1 Control rats have significantly higher
terminal fasting blood glucose when compared to LEW/SsNHsd rats. Data are expressed as the
mean with SD. n=8, group different letters represent p<0.05.
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TNF-1a level is significantly low in LEW.1WR1 rats compared to LEW/SsNHsd rats.TNF-a levels
were elevated in both treated rat groups compared to their control rat group. Fold change of TNFa is significantly elevated with LEW.1WR1Treated rats compared to control LEW.1WR1 rats and
LEW/SsNHsd rats. TNF a level is trending upward with PIC treatment in both strains.

Figure 6. Rat cytokine TNF-a level in serum multiplex data.
LEW/SsNHsd Control, LEW/SsNHsd Treated, LEW.1WR1 Control, LEW.1WR1 Treated rat
groups respectively. n=8,8,7,8. b Fold change of TNF-a in LEW.1WR1rats. Different letters
represent significance among groups (p<0.05).
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Figure 7 a. Terminal proinflammatory, anti-inflammatory cytokine levels of 4 different rat groups
LEW/SsNHsd Control, LEW/SsNHsd Treated, LEW.1WR1 Control, LEW.1WR1 Treated rat
groups respectively. IL-12 (n=5,7,4,3), IL-18 (n=7,7,4,6), IL-17 (n=8,8,6,7) and IL-4(n=8,8,7,7)
,IL-10(n= 8,8,3,4) The Different letters represent significant differences between groups. (p<0.05).

Figure 7b. Fold changes of proinflammatory cytokines.
Fold change was only calculated in groups n <7 samples.Fold change was calculated in 4 different
rat groups starting from LEW/SsNHsd Control, LEW/SsNHsd Treated, LEW.1WR1 Control,
LEW.1WR1 Treated rat groups respectively.
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Both Treated rat groups have elevated pro inflammatory cytokine level compared to control groups
respectively. There is significant difference between two rat strains and LEW.1WR1rats have
significantly low pro inflammatory cytokine levels compared to SsNHsd groups. Fold changes are
determined due to strong strain effect which covered the effect of the treatment.IL-17 and IL- 12
fold changes are elevated in both treated rat groups compared to control rat groups.IL-4 level is
elevated in PIC treated SsNHsd rats compared to SsNHsd control rats while IL-4 level is decreased
in PIC treated LEW.1WR1rats compared to LEW.1WR1control rats.IL-18 fold changes cannot be
performed due to less number of samples.
Then we assessed hormones in the blood. PYY, PP, LEPTIN, GLP-1 (Glucagon-like peptide-1),
Amylin expression significantly increased in LEW.1WR1 treated rats compared to 1WR1 control
rats. LEW/SsNHsd treated rats have lower expression of amylin compared to SsNHsd control rats.
GIP (Gastric inhibitory polypeptide) expression increased in 1WR1 rats. Ghrelin levels increased
in both treated rat groups compared to their related control rat groups. GIP (Gastric inhibitory
polypeptide) level increased in the LEW.1WR1 treated group compared to LEW.1WR1 rats and
both LEW/SsNHsd rat groups. GLP-1(Glucagon-like peptide-1) hormone level increased in
LEW.1WR1. There is no significant difference between each rat group. Leptin is no significant
difference between each group. PP level significantly differences among two rat groups. PYY
level is not significantly different among rat groups. But LEW.1WR1 treated rats showed increased
PYY level compared to LEW.1WR1 control rats.
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Figure 8. Rat Metabolic Hormone Level Multiplex data.
Starting from top Amylin- (n=7,8,2,4 ) were presented for Ghrelin(n=6,6,5,7), GIP-Gastric
inhibitory polypeptide (n=7,7,8,8) GLP-1-Glucagon-like peptide-1(n=8,8,8,8), Glucagon
(n=8,8,7,8),

Leptin(n=8,8,8,8),

PP-Pancreatic

polypeptide

(n=8,8,7,8),PYY-Peptide

YY

(n=8,8,7,8) LEW/SsHNsd Control, LEW/SsHNsd Treated, LEW.1WR1 Control ,LEW.1WR1
Treated groups. One way ANOVA with multiple comparisons were done. Error bars represent
standard deviation p<0.05.

45

Fold change of GIP, GLP-1, PP, Glucagon, Leptin and PYY in LEW/SsNHsd and LEW.1WR1
control and treated rats. Fold change was done with number samples < 7 groups.

GIP, GLP, Leptin levels are increased in IWR1 Treated rats compared to 1WR1 Control rats.
Glucagon, PP, PYY levels are decreased in LEW.1WR1 treated rats compared to control rats. PP,
GIP, Glucagon levels decreased in LEW/SsNHsd treated rats compared to LEW/SsNHsd control
rats. PYY and GLP-1 levels are barely changed with Poly IC treatment in LEW/SsNHsd rats.
Leptin level increased in LEW/SsNHsd treated rats compared to LEW/SsNHsd control rats.
Because of huge strain differences, PIC effect was masked. We performed fold changes by
normalizing data to each control strain. We observed that GIP level is significantly increased in
LEW.1WR1 treated rats compared to control rats. GIP level is trending downward in
LEW/SsNHsd rats with PIC treatment while GIP level is significantly upward in LAW.WR1

46

treated rats compared to control LEW.1WR1 rats. Glucagon level is not significantly different
among each group but, trending downward with PIC treatment in both treated groups. PYY level
is significantly increased in LEW.1WR1treated rats compared to other groups.

Figure 9a. Histology of the CD3 stained pancreases.
+

Treatment rats show increased T cell staining. (A) to the top left is the LEW.1WR1-Control, (B)
to the top right is LEW.1WR1-Treated, (C) to the bottom left is LEW/SsNHsd-Control, and (D)
to the bottom right is the LEW/SsNHsd-Treated. Islets were circled. II.) Average CD3 infiltration
+

scores. Data are expressed as mean with SD P<0.005 n=4,8,8,8 for in LEW.1WR1 Control,
LEW.1WR1 Treated, LEW/SsNHsd Control LEW/SsNHsd Treated groups respectively.GLP-1
level is significantly increased in LEW.1WR1 treated rats compared to LEW/SsNHsd treated rats.
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In figure 3 that 1WR1 rats have blood glucose levels high as 150mg/dL, which is higher than
SsNHsd rats, but it is below hyperglycemic levels. The CD3 (cluster of differentiation 3) T cell
co-receptor helps to activate both the cytotoxic T cell (CD8+ naive T cells) and also T helper cells
(CD4+ naive T cells). Both treated rat groups have high CD 3 cells compared to their control rat
groups. SsNHsd treated rats have significantly high; average CD3 infiltration score compared to
LEW/SsNHsd control rat groups. Then LEW.1WR1 Treated rat group has a significantly high;
average CD3 infiltration score compared to control LEW.1WR1 rats. But LEW/SsNHsd treated
and LEW.1WR1 control rat group infiltration scores are not significant.LEW.1WR1 rats have
significantly high infiltration scores compared to SsNHsd rats suggesting poly IC induction causes
to activate inflammation signals in both rat groups. By looking at CD3 stain and blind scoring, it
seems like that 1WR1 Rats have infiltration scores in 2-3 range, slightly less than what we
expected.
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Figure 9b. Histology of the CD68 stained pancreases.
+

Currently point there is low grade CD68 staining in the islets of the treated rats. (A) to the top left
+

is the LEW.1WR1-Control, (B) to the top right is LEW.1WR1-Treated, (C) to the bottom left is
LEW/SsNHsd-Control, and (D) to the bottom right is the LEW/SsNHsd-Treated. Islets were
circled. II.) Average infiltration of CD68 cell scores. Data are expressed as mean with SD P<0.005
+

n=4,8,8,8 for

in LEW.1WR1 Control, LEW.1WR1 Treated, LEW/SsNHsd Control

LEW/SsNHsd Treated groups respectively.

CD68 is a protein highly expressed by cells in the monocyte lineage, by circulating macrophages,
and by tissue macrophages again giving the signal of started inflammation. LEW/SsNHsd control
is a significantly low infiltration score compared to LEW.1WR1 treated rats. Again, that
LEW.1WR1 rats have high infiltration scores compared to LEW/SsNHsd rats.LEW.1WR1 rats
have a high infiltration score even without giving Poly IC control. Even looking at the islets, it
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observed that 1WR1 rats have small islets compared to SsNHsd rats. When looking at the CD68
stain, the values range between 1-1.5 slightly less than CD3.

Figure 9 c. Histology of the insulin stained pancreases.
The LEW.1WR1 rats showed a significantly lower number of total islets. (A) to the top left is the
LEW.1WR1-Control, (B) to the top right is LEW.1WR1-Treated, (C) to the bottom left is
LEW/SsNHsd-Control, and (D) to the bottom right is the LEW/SsNHsd-Treated. (Red stained
clusters of cells are islets). II)A-E Semiquantitative analysis of islets and size. Data are expressed
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as mean with SD. P<0.005 represents n=4,8,8,8 for in LEW.1WR1 Control, LEW.1WR1 Treated,
LEW/SsNHsd Control LEW/SsNHsd Treated groups respectively.

In figure 9 insulin-stained islets separated by extra small, small, medium, large size. When looking
at blind scoring data, 1WR1 rats have a significantly lower number of extra small and small islets
compared to control groups. 1WR1 has an overall lower number of islets compared to control
groups.
The results we got support the previous studies by showing the infiltration of CD3 increases
infiltration of CD68.The staining of CD68 cells supports that insulitis has an essential role to play
in insulitis (Willcox A et al.,2009). The results also verified the time point we choose that rats are
not in full-blown diabetic, but they are growing toward that point as is growing infiltration of
immune cells. (Magnuson AM et al.,2015). We have observed that at 12 days, a significant number
of rats have infiltration 3-4 levels of both CD3 and CD68 in their islets. Most of the stained cells
located in the periphery. On day 6, the rats were normoglycemic; by looking at CD3 stain and
+

blind scoring, it seems like that 1WR1 Rats have infiltration scores in 2-3 range, slightly less as
we expected. We don’t want them to be diabetic. When looking at the CD 68 stained cells, the
+

values changed between 1-1.5 slightly lesser than CD3 scores. The scores for treated animals are
+

higher compared to control groups. This result is the same for both rat groups. In figure
9.LEW/SsNHsd treated rats have increased number of islets compared to control LEW/SsNHsd
rats. Even though, LEW.1WR1treated rats have decreased number of islets compared to control
LEW.1WR1 rats. It seems like that LEW/SsNHsd rats have compensatory mechanism to save
islets and 1WR1rats do not.
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Figure 10. Serum insulin level from multiplex data for 4 rat groups.
LEW.1WR1 rats have significantly high insulin concentration compared to LEW/SsNHsd control,
LEW/SsNHsd rats. Error bars are SD of n=8, 5, 5, & 3 respectively and dark square for
LEW/SsNHsd rats and dark circle for LEW.1WR1. Error bars reflect standard deviation P<0.05.
1WR1 rats Blood insulin levels are significantly higher compared to SsNHsd rats. But SsNHsd
rats’ insulin levels are below the range and cannot be detected by multiplex. C-peptide produces
when proinsulin is cleaved to produce insulin. Assessing the C-peptide data blood insulin should
be a measurable. But insulin level for most of SsNHsd rats are below the range of Multiplex we
used.
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Figure 11. C-peptide level for 4 rat groups.
LEW/SsNHsd treated rats have significantly low C-peptide concentration compare to
LEW/SsNHsd control, LEW.1WR1 Control, LEW.1WR1 Treated rats. n=8, 8, 8, & 8 for
LEW/SsNHsd Control LEW/SsNHsd Treated groups, LEW.1WR1 Control, LEW.1WR1 Treated
groups respectively. Error bars reflect standard deviation. P<0.005.
We have observed that C-peptide levels are above 300pg/mL which is measurable for all for
groups. C-peptide level is significantly decreased in LEW/SsNHsd treated rats compared to control
LEW/SsNHsd rats and LEW.1WR1 rats
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Figure 12. Triglyceride concentration in serum for 4 rat groups.
LEW/SsNHsd treated rats have significantly high triglyceride concentration compare to
LEW/SsNHsd control, LEW.1WR1 Control, LEW.1WR1 Treated rats. n=8, 8, 8, & 8 for
LEW/SsNHsd Control LEW/SsNHsd Treated groups, LEW.1WR1 Control, LEW.1WR1 Treated
groups respectively. Error bars reflect standard deviation. P<0.005.
Cholesterol concentration of liver for 4 rat groups. n=8, 8, 8, & 8 for groups, LEW/SsNHsd
Control, LEW/SsNHsd Treat, LEW.1WR1 Control, LEW.1WR1 Treated ed respectively. Error
bars reflect standard deviation. P<0.005.LEW.SsHNsd Treated rats have significantly high
Cholesterol concentration compared to LEW/SsNHsd control, LEW.1WR1 Treated, LEW.1WR1
control rats.
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Figure 12. Triglyceride concentration of liver for 4 rat groups.
LEW/SsNHsd control rats have significantly low compared to LEW/SsHNsd treated, LEW.1WR1
Treated rats. n=8, 8, 8, & 8 for LEW/SsNHsd Control LEW/SsNHsd Treated groups, LEW.1WR1
Control, LEW.1WR1 Treated, respectively. Error bars reflect standard deviation. P<0.005

Since1WR1 rats are known to express the FAT 10 gene in response to TNFa. The liver is one of
the organs that overexpress the FAT 10 gene and a significant regulator of metabolism. So, we
looked at significant differences in lipid metabolism, which is regulated by insulin and altered
when FAT 10 knock out.
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Figure 14. Gene expression analysis of UBD and p53 in liver.
LEW.1WR1 Control rats have significantly higher expression of UBD and P53 in liver compared
to LEW/SsNHsd rats. Gene expression analysis of UBD and p53 in the liver. n=8, 8, 7, & 7 for
Ubd and n=8, 8, 8, & 5 for p53 in LEW.1WR1 Control, LEW.1WR1 Treated, LEW/SsNHsd
Control LEW/SsNHsd Treated groups respectively. Error bars reflect standard deviation. P<0.005.

Figure 15. Insulin induce Relative gene expression of liver genes
FOXO1 involved in cholesterol synthesis and SREBP-1(Sterol regulatory element-binding
transcription factor 1), SCD-1(Stearoyl-CoA desaturase-1), was tested in LEW/SsNHsd
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Control,LEW/SsNHsd Treated, EWLEW.1WR1 control, LEW.1WR1 Treated rats. FOXO1
expression was significantly high in LEW.1WR1treated rats. Error bars reflect standard deviation.
P<0.005.

Figure 16. Relative gene expression of lipolytic liver genes
Adipose triglyceride lipase (ATGL), Acyl-CoA Synthetase Long Chain Family Member
1(ACSL1), and Patatin Like Phospholipase Domain Containing 2 (PNPLA2), CPT-1(Carnitine
palmitoyltransferase 1 ) involved in was tested in LEW/SsNHsd Control, LEW/SsNHsd Treated,
LEW.1WR1 control,LEW.1WR1 Treated rats.
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Figure 17. Relative gene expression of lipogenic liver genes
FASN ( Fatty acid synthase), SCD-1(Stearoyl-CoA desaturase-1), DGAT1(Diacylglycerol OAcyltransferase 1), DGAT2 (Diacylglycerol O-Acyltransferase 2), were tested in LEW/SsNHsd
Control, LEW/SsNHsd Treated, LEW.1WR1 control, LEW.1WR1 Treated rats. Error bars reflect
standard deviation. P<0.005.
LEW.1WR1 control rats have significantly increased DGAT1, DGAT2 compared to SsNHsd
control and SsNHsd treated rats. On the otherhand, SCD-1, FASN are significantly reduced in both
control and treated 1WR1rats compared to SsNHsd rats.SCD-1 significantly decreased SsNHsd
treated rats compared to Control rats. DGAT1, DGAT2 expression levels are significantly
increased in LEW.1WR1 control rats compared to LEW.1WR1 treated rats.
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Figure 19. Relative gene expression of gluconeogenic/ glycogenolysis liver genes
GLUT2(Glucose transporter 2), G6PC (Glucose-6-Phosphatase Catalytic Subunit), GAPDH
(Glyceraldehyde 3-phosphate dehydrogenase), PCK-1 (Phosphoenolpyruvate carboxykinase 1)
were tested in LEW/SsNHsd Control, LEW/SsNHsd Treated, LEW.1WR1 control,LEW.1WR1
Treated rats. Error bars reflect standard deviation. P<0.005.

G6P levels are significantly increased in LEW.1WR1 rats compared to LEW/SsNHsd rats.On The
other hand, GAPDH and GLUT2 expression levels of LEW.1WR1 rats are significantly lower
compared to SsNHsd rats.PCK-1 expression level is increased in LEW/SsNHsd treated rats
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compared to LEW/SsNHsd rats. On The other hand, LEW.1WR1 treated rats have significantly
lower gene expression compared to LEW.1WR1 control rats.

Figure 20. Relative gene expression of glycolytic liver genes
Carbohydrate

responsive

element

binding

Protein

(ChREBP-1),

(Phosphofructo-2-

Kinase/Fructose-2,6-Bisphosphatase 3 (PFKFB3) were tested in LEW/SsNHsd Control,
LEW/SsNHsd Treated, EWLEW.1WR1 control, LEW.1WR1 Treated rats. Error bars reflect
standard deviation. P<0.005.

Glycolytic gene PFK3b, ChREBP-1 expression are significantly increased in LEW/SsNHsd
treated rats compared to all the other groups. PFK3b, ChREBP-1 expressions are significantly
lower in LEW.1WR1 treated rats compared to LEW.1WR1 control rats.
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Figure 21. Relative Gene expression of inflammation liver genes IFNbeta
IFNbeta involved in immune response was tested in LEW/SsNHsd Control, LEW/SsNHsd
Treated, LEW.1WR1 control, LEW.1WR1 Treated rats. Error bars reflect standard deviation.
P<0.005.

IFN beta gene expression level is significantly increased in LEW.WR1 treated rats. IFN beta gene
expressions are lower in LEW/SsNHsd control, LEW/SsNHsd treated, LEW.1WR1 control rats.
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Discussion
It is known that environmental factors are associated with Type 1 diabetes (Atkinson, et al.,2014).
The LEW.1WR1 rat model is triggered by Poly IC leading to the development of Type 1 diabetes.
The susceptibility of this model has been shown to be related to the Type 1 Interferon receptor as
well as an over expression of FAT10, but to date there have been no studies to understand the
condition of the islets prior to insulitis or the metabolic condition of the rats during the time
window we have chosen (Natasha Q et al.,2017). According to Atkinson et al., glucose fluctuation
can be observed in humans at the onset of diabetes, yet it is not clear how it correlates to
metabolism prior to autoimmunity. At the onset of diabetes, there is a phase denoted the
“Honeymoon phase” (Partial remission phase) where insulin requirement is low (<174 pmol/L) (
Bernard P et al., 1985) This phase is not clearly characterized since biopsy for human patients at
this stage is detrimental to many processes as the pancreas has both endocrine and exocrine
functions. We characterized the Day 6 time point in the 1WR1 rat to analyze the model at a time
point preceding significant insulitis.
There were no significant weight differences during the induction period across the four groups
(Figure 1). LEW/SsNHsd rats maintain (90mg/dL±) terminal fasting blood glucose level while,
1WR1 treated rats are maintaining a 150 mg/dL± (Figure 2) Diabetic rats have severely increased
fasting blood glucose levels above 250 mg/dL which called “hyperglycemic” neither strain had
hyperglycemia. (Anne J et al., 2005). GLUT2 is glucose transporter isoform 2, Glut2 is
predominantly expressed in the liver and pancreas, suppression of Glut2 expression revealed the
reduce uptake of glucose in liver (Thorens B et al., 2015) in LEW.1WR1 rats compared to SsNHsd
rats. The treatment effect is not very visible at this stage.
62

Next, we assessed the stage of insulitis. For this we had blinded scorers grade the infiltration of
the islet for CD3+ and CD68+ stained cells levels to evaluate T cell or macrophage, dendritic cell
and monocyte infiltration respectively. When LEW.1AR1/Ztm-iddm rats were transitioning from
normoglycemia to hyperglycemia at an early stage of infiltration, macrophages were predominant
at infiltration of islets. 60-70% of β cell loss was linked to T cell infiltration (Anne J et al.,2005).
In the beginning of islets infiltration, immune cell infiltration is limited to the peripheral region of
islets. As the disease progresses, the whole islet is infiltrated. Immune cells circulate in the blood
and enter the pancreas through ducts, capillaries, and blood vessels. Most of the macrophages and
T cells in all four rat groups are located in the ducts and not in the core of the islets at this time
point. It has been previously reported that infiltration of CD3+ cells tend to precede the increase in
CD68+ cells, LEW.1WR1 treated rats at this time point have the average CD3+ staining of a level
of 3 while CD68+ cells have the average staining of a level of 1.5 and are not heavily infiltrating
islets at the Day 6 time point. (Martha CT et al.,2016), (Mordes J et al., 2005). There are small
amounts of T Cells and Macrophages present even in the control islets and pancreases as immune
cells general survey organs to detect invasion.
Serum IL-17 levels are increased in both treated rats. CD 3+ levels are also increased in both PIC
rat groups .CD3 stain is staining every kind of T cell in pancreases including Th17 T Cells. IL-17
plays a crucial role in various inflammatory responses and autoimmune diseases. Recent studies
have shown increased IL-17 in STZ (streptozotocin)induced diabetic animal models and non-obese
diabetic model (NOD) mice. Even though we observed increased T Cells in pancreases with PIC
treatment, those T Cells have not invaded the islets yet. Most of the stain patches are located in
ducts near to islets.
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Ryan A et al., 2014 observed a significant increase in infiltration of the islet by T cells on day 7 in
Poly IC induced LEW.1WR1 rats. The scores of CD3+ and CD68+ together combined with the
fasting blood glucoses reflect a low overall insulitis score which indicates that the rats do not have
full blown diabetes at the time point we selected.
These animals also have a difference in blood insulin concentration independent of PIC injection;
1WR1 rats have high insulin levels compared to LEW/SsNHsd rats. Which suggests that the islets
are either overproducing insulin or that there may be reduced insulin efficiency suggesting two rat
strains may have different metabolic phenotypes. Previous findings showed that insulin transcripts
in the pancreas of the 1WR1 rat are increased at day 7 during induction, but this paper did not
compare these levels to control 1WR1 rats (James E et. al., 2014).
The result of the insulin stained sections was unexpected since 1WR1 rats have a lower number of
small, extra small and total islets and compared to SsNHsd rats (Figure 8) yet they have
significantly increased insulin levels (Figure 8). The results from CD3 and CD68 staining shows
that rats do not have significant infiltration yet the insulin staining in the control 1WR1 rat pancreas
suggests that there may be fewer islets in the beginning. Having fewer islets can reduce the ability
of the rat to maintain a honeymoon phase as significant beta cell death would have a much larger
impact on residual beta cell mass. It is observed that LEW/SsNHsd treated rats have high numbers
of large and medium and islets while LEW.1WR1treated rats have decreased numbers of islets
compared to both LEW/SsNHsd rat groups and LEW.1WR1control rats. We hypothesize that
SsNHsd treated rats compensate for beta cell destruction by proliferating and 1WR1 treated rats
cannot compensate for the beta cell destruction since they have a small number of islets at the
beginning. Ki67 like staining has to be done to confirm the differences in proliferation rate. The
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insulin levels, c-peptide levels and ß cell staining also support that the rats from two rat groups
have not developed full blown diabetes at the time point we choose.
The data from serum chemokine and cytokine array suggests that 1WR1 rats have different
inflammatory responses than the SsNHsd rats. According to Natasha Qaisar et al., 2017 interferon
receptor mediated signaling pathway (IFN pathway) and type 1 Interferon plays a major role in
virus induced type 1 diabetes in LEW.1WR1 rats. Disrupting IFN pathway or IFN production can
delay or prevent development of type 1 diabetes in LEW.1WR1 rats. But, IFN-γ values in both
strains at this time point are below the detectable level of the assay. It is unclear at this time point
how the IFN pathway is involved during PIC induction. So, as a future study we are hoping to look
at IFN a and IFN beta expression levels in splenocytes. IL-1 β and TNFα crucially determines the
fate of β cells through recruiting, activating and proliferating immune cells (Fernanda O et al.,
2010). It is known that proinflammatory cytokines play a role in apoptosis of β cells (Thomas HE.,
et al.,2013) (Anne J. et al 2005). We observed that TNF α increased in both rat groups with Poly
IC induction. IL-1β is trending higher but IL-1β levels in most samples were not detectable because
the lifetime of IL-1ß is around 4 hrs and we kept them for more than 7 hrs to do post injections
analysis. We observed no significant difference in proinflammatory cytokines like IL-18 and IL12 in LEW.1WR1 rats at 6-day time point.
On the other hand, anti-inflammatory signals like IL-4 are lower with PIC treatment in
LEW.1WR1 rats while SsNHsd treated rats have increased IL-4 levels. IL-4 participates in lipid
metabolism and diabetic susceptibility. IL-4 improves insulin sensitivity and glucose tolerance
while inhibiting lipid accumulation (Ming-Yuh S et al., 2019). LEW.1WR1 rats have increased
blood glucose levels and are less insulin sensitive according to our data. SsNHsd rats are
normoglycemic and maintained normal blood insulin levels during the duration of the experiment.
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Increased IL-4 level in SsNHsd rats correlates with improved insulin sensitivity, glucose tolerance
and lipid accumulation in the liver. TNF and IFN β are major effectors of immune responses which
eventually leads to production of pro/anti-inflammatory signals like IL-6 and IL-10 .IL-6-IL-10
levels are not significantly different with treatment but with strain. But we observed elevated levels
of IL-6, IL-10 cytokine levels in serum with PIC treatment as sign of inflammation.
Increased insulin and high terminal blood glucose levels in the control 1WR1 rat suggest that
LEW.1WR1 rats have aberrant glucose and insulin homeostasis. We have observed a phenotypic
strain difference in blood glucose and insulin as well as low numbers of islets in 1WR1 rats. It is
clear that there is a definitive correlation between hormones and blood glucose levels, insulin
sensitivities and other possible effects related to T1D susceptibility.
Other serum hormone levels were also changed with treatment and or difference between rat strain.
GLP-1, leptin, amylin, ghrelin is positively correlated with the serum cholesterol. Leptin is
inversely related with Triglycerides. Poly IC treated SsNHsd rats have significantly high levels
compared to SsNHsd rats, LEW.1WR1 rat groups possibly depositing cholesterol in the liver. On
the other hand, Leptin helps to maintain insulin level in blood, and it is observed that 1WR1rats
have reduced level of leptin with Poly IC induction
PP, PYY, and ghrelin are hormones all produced in the digestive system. These hormones are
called hunger hormones and the level of these hunger hormones decreased in LEW.1WR1 rats.
Ghrelin plays a role in glucose metabolism, food intake, and insulin metabolism. Ghrelin inhibits
insulin release in order to prevent cell death in the pancreatic β cell line. It is observed that both
Poly IC induced rat groups have high ghrelin levels suggesting trying to prevent dying of β cells
(Andralojc K et al.,2014). PYY is strongly correlated with decreased sensitivity insulin (Viardot
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A et al., 2008). PYY level is also increased in treated 1WR1 rats which means LEW.1WR1rats
are losing insulin sensitivity.
GLP-1 is known to induce the insulin secretion of β cells through ion channels. GLP-1 increased
with 1WR1 rats with Poly IC treatment compared to 1WR1 control rat group. Since Treated
LEW.1WR1 rats have high insulin level again send us to the same direction that increase GLP-1
is correlated with high insulin level. But is not really changed with SsNHsd rats which is again
suggests that two rat groups are regulating different pathways in response to Poly IC induction.
(Patrick E et al., 2002).
SsNHsd rats have increased serum cholesterol and triglyceride levels compared to 1WR1rats. On
the other hand,1WR1 rats have lower serum triglyceride and serum cholesterol levels with higher
triglyceride levels in the liver. LEW/SsNHsd rats/It seems like LEW.1WR1 rats start storing
triglyceride in the liver and probably start using them as energy sources. So, we decided to look at
lipolysis and lipogenesis gene expression in the liver. LEW.1WR1 rats over expressed fat10 gene
which makes them susceptible to develop T1D.The liver is one of the organs that will over express
fat10 gene. Overall, the fat10 gene role is not entirely understood. fat10 knockout mice have less
adiposity and extended life span by 20% compared to their C57B6 mice (Canaan A et al., 2006).
Those mice used fat as fuel for metabolism, reduced blood insulin levels and glucose levels and
increased insulin sensitivity were observed (Canaan A et al., 2014). Conversely, fat10
overexpression in 1WR1 rats can be responsible for higher terminal fasting blood insulin and
glucose levels.
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TNF-α plays a role in stimulating lipolysis and increasing lipolytic rate. This could be due to TNFα activating extracellular signal-related kinase, ERK 1 and ERK2 (Ryden L et al. 2002) and
downregulating lipid droplet-associated protein perilipin (PLIN) which we did not measure.
Erk1/2 has implicated in several diseases and chronic inflammations and plin2 promotes lipid
accumulation in liver. TNF-α levels are increased in LEW.1WR1 and LEW/SsNHsd treated rats’
serum potentially leading to increased lipolysis. TNF-α levels correlate with increased lipolytic
gene expression in pnpla2, atgl, acsl-1 in treated rat groups compared to respective control groups.
Overall SsNHsd rats have lower expression of lipolytic genes and fatty acid oxidation genes
compared to LEW.1WR1rats. Both LEW.1WR1 rat groups showed significantly high liver gene
expression of cpt-1, a gene related to fatty acid oxidation.
LEW.1WR1 rats have increased lipogenic gene expression in the liver including SREBP-1. The
transcription factors SREBP-1 and PPARα regulate lipid storage in the body (Jump DB et al.,
2011). Insulin induces the sterol regulatory element binding protein-1 (SREBP-1) nuclear
abundance through several mechanisms like transcription of the SREBP-1 gene and stabilizing
SREBP-1 mRNA (Jump DB et al.,2008). SREBP-1 stimulates synthesis of fatty acids in the liver
(Iichiro S et al., 1999). SREBP-1 gene expression level is increased twice as much as control
LEW.1WR1 rats in treated LEW.1WR1 suggesting that 1WR1 treated rats have high fatty acid
deposition in the liver with PIC treatment. (Renate S et al., 2019). diglyceride acyltransferase 1
and 2 (DGAT1 and DGAT2) catalyzes the formation of triglycerides from diacylglycerol and
Acyl-CoA (Chi-Lian et al., 2008) which is significantly increased in LEW.1WR1 rats compared
to SsNHsd rats.

Stearoyl-CoA Desaturase-1(scd-1) catalyzes the rate-limiting reaction of

monounsaturated fatty acid (MUFA) synthesis. (Sudha B. et al., 2006) Loss of scd-1 improves
insulin sensitivity in lean mice (Flowers J. et al., 2007) and significantly low expression of scd-1
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and in LEW.1WR1 rats compared to SsNHsd rats correlates with reduced insulin sensitivity. Both
rat groups treated with poly IC had reduced expression of SCD1 and this could be related to ER
stress responses as the islets in LEW.1WR1 rats at day 8 have been observed to have increased
phosphatidylcholine, a marker of ER expansion in response to poly IC treatment.
Both control and treated LEW.1WR1 rats have high Glucose 6 Phosphatase (g6pc) and FOXO-1
gene expression and reduced PCK-1 expression compared to SsNHsd rat strain. G6pc converts
Glucose 6 phosphate to glucose as the final step of gluconeogenesis while pck-1 is the second step
of glucose synthesis from pyruvate. Both of these enzymes are regulatory steps in the pathway,
but glucose 6 phosphate can be synthesized through other pathways like the pentose phosphate
pathway. Foxo1 regulates gluconeogenesis in the liver by increasing expression of gluconeogenic
genes. PGC-1α can robustly activate G6pc and pck-1. However, FOXO1 markedly diminished the
ability of PGC-1α

to activate pck-1 and G6pc genes. Hepatic gluconeogenesis is absolutely

necessary during prolonged fasting and we have fasted our rats for 7 hours which probably causes
an increased G6pc and FOXO-1 expression in LEW.1WR1 rats.
ChREBP-1(Carbohydrate Responsible binding protein -1) plays a role in glycolysis, is
significantly lower in both control and treated LEW.1WR1 rats compared to SsNHsd rats. On The
other hand, SsNHsd rats have high expression of ChREBP-1 and increased the expression with
PIC treatment. SsNHsd rats have high gene expression related to glycolysis compared to SsNHsd
rats and PIC treatment can elevate the effect at this stage. p53 downregulates glycolysis in liver.
We have observed overexpressed p53 rats causing down regulation of Pck-1(Zhang P.et al., 2014)
in LEW.1WR1 rats. Leptin stimulates Pfk3 expression which also leads to glycolysis, in
hepatocyte cells (Jonathan D. et al., 2018). We have observed decreased leptin levels and Pfk3 in
LEW.1WR1 treated rats compared to control LEW.1WR1 rats suggesting down regulated
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glycolysis in the liver. On the other hand, treated SsNHsd rats have significantly high P53, Pfk3
gene expression and leptin level compared to SsNHsd control rats which suggests increased
glycolysis in the liver with PIC treatment.

Conclusion

According to the data we gathered that LEW.1WR1 rats are losing insulin sensitivity, ß cells in
the pancreas increase insulin production. The reduced insulin sensitivity makes LEW1.WR1 rats
to increase triglyceride usage and production in the liver. And LEW.1WR1rats have reduced
glycolysis and increased gluconeogenesis in the liver.

70

References
Akerblom HK, Vaarala O, Hyöty H, Ilonen J, Knip M,Environmental Factors in the Etiology of
Type 1 DIabetes, 2002, Am J Med Genet 115: 18– 29
Al-Awar, A., Kupai, K., Veszelka, M., Szucs, G., Attieh, Z., Murlasits, Z,Varga, C Experimental
Diabetes Mellitus in Different Animal Models,2016,Journal of Diabetes Research
Allen HF, Klingensmith GJ, Jasen P, Effect of bacillus Calmette -Guerin vaccination on new onset
T1D-a randomized clinical study,1999, Diabetes Care, 22:1703-1707
Arndt T, Jörns A, Hedrich HJ, Lenzen S, Wedekind D. Variable immune cell frequencies in
peripheral blood of LEW.1AR1-iddm rats over time compared to other congenic LEW
strains,2014, Clin Exp Immunol,177(1):168–178.
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes, 2014, Lancet,383(9911):69–82.
Baggio, L. L., D. J. Drucker. Biology of incretin, GLP-1 and GIP, 2007, Gastroenterology 132:
2131–2157.
Bao M, Yang Y, Jun HS, Yoon JW. Molecular mechanisms for gender differences in susceptibility
to T cell-mediated autoimmune diabetes in nonobese diabetic mice 2002, J. Immunol, 168:5369–
5375.
Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE Ubiquitin-like protein conjugation and the
ubiquitin-proteasome system as drug targets, 2011, Nat Rev Drug Discov 10:29-46
Blankenhorn E P, Cort L, Greiner DL, Guberski D L, Mordes J P ,Virus-Induced Autoimmune
Diabetes in the LEW.1WR1 the Major Histocompatibility Complex, 2009 ,Diabetes,(58).
Blankenhorn E, .Diubiquitin (Ubd) is a susceptibility gene for virus-triggered autoimmune
diabetes in rats, 2014, Genes Immun,15(3), 168–175.
Blankenhorn EP, Cort L, Greiner DL, Guberski DL, Mordes JP. Virus-induced autoimmune
diabetes in the LEW.1WR1 rat requires Iddm14 and a genetic locus proximal to the major
histocompatibility complex,2009, Diabetes,58(12):2930-8.
Blankenhorn EP, Rodemich L, Martin-Fernandez C, Leif J, Greiner DL, Mordes JP. The rat
diabetes susceptibility locus Iddm4 and at least one additional gene are required for autoimmune
diabetes induced by viral infection, 2005, Diabetes,54(4):1233–1237.
Bonifacio E, Ziegler AG. Advances in the prediction and natural history of type 1 diabetes, 2010,
Endocrinol Metab Clin North Am. 39:513–25
Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with
autoimmune polyendocrine deficiencies,1974, Lancet, 2(7892):1279–83

71

Broughton S. E, Petersen J, Theodossis A, Scally S W., Loh K L., Thompson A, Rossjohn J,Biased
T Cell Receptor Usage Directed against Human Leukocyte Antigen DQ8-Restricted Gliadin
Peptides Is Associated with Celiac Disease. 2012, Immunity, 37(4), 611–621.
Campbell-Thompson M, Fu A, Kaddis J S, Wasserfall C, Schatz, DA, Pugliese A, Atkinson M. A,
Insulitis and β-cell mass in the natural history of type 1 diabetes,2016, Diabetes, 65(3), 719–731.
Campbell-Thompson ML, Atkinson MA, Butler AE, The diagnosis of insulitis in human type 1
diabetes,2016, Diabetologia 56:2541–2543
Canaan A, DeFuria J, Perelman E, Schultz V, Seay M, Tuck D,Weissman S. M.,Extended Lifespan
and Reduced Adiposity in Mice Lacking the FAT10 gene,2014, Proceedings of the National
Academy of Sciences of the United States of America, 111(14), 5313–5318.
Cardozo AK, Kruhoffer M, Leeman R, Orntoft T, Eizirik DL. Identification of novel cytokineinduced genes in pancreatic beta-cells by high-density oligonucleotide arrays. ,2004, Diabetes,
50(5):909–20.
Centers for disease control and prevention. national diabetes statistics report, 2017. Atlanta, GA:
centers for disease control and prevention, U.S. dept of health and human services
Chabot F, Caron A, Laplante M, St-Pierre DH. Interrelationships between ghrelin, insulin and
glucose homeostasis: Physiological relevance, 2015, World J Diabetes. (3):328–341.
Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL. Monocyte chemoattractant protein-1 is
expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed
human and rat islet cells,2011, Diabetologia,44(3):325–32
Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor
axis, insulin and cancer risk,2011, Nature Reviews Endocrinology,7(1):11-24.
Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG. Inverse relationship between
cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. 2001,
Diabetes, 50(8):1771–7
Collier J J, Burke SJ, Eisenhauer M E, Lu D, Sapp R C, Frydman C J, Campagna SR,Pancreatic
β-cell death in response to pro-inflammatory cytokines is distinct from genuine
apoptosis,2011,PLoS ONE, 6(7).
Cort L, Habib M, Eberwine R A, Hessner M J, Mordes J P, Blankenhorn E , Diubiquitin (Ubd) is
a susceptibility gene for virus-triggered autoimmune diabetes in rats,2014,Genes and Immunity,
15(3)
Dai XQ, Plummer G, Casimir M, Kang Y, Hajmrle C, Gaisano HY, Manning Fox JE, MacDonald
PE, SUMOylation regulates insulin exocytosis downstream of secretory granule docking in
rodents and humans,2011, Diabetes, 60:838-847

72

Defuria, Jason, Deletion of FAT10 Gene Alters Energy Homeostasis in Mice. Dissertation, 2011,
Tufts University, UMI, 3481177
Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, Mosca F, Boggi U, Muda
AO, Prato SD, Elliott JF, Covacci A, Rappuoli R, Roep BO, Marchetti P: Coxsackie B4 virus
infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients, 2007,
Proc Natl Acad Sci U S A 104: 5115–5120
Eberwine RA, Cort L, Habib M, Mordes JP, Blankenhorn EP. Autoantigen-induced focusing of
Vβ13+ T cells precedes onset of autoimmune diabetes in the LEW.1WR1 rat. 2014, Diabetes,
63(2):596–604
Eberwine, R. A., Cort, L., Habib, M., Mordes, J. P., & Blankenhorn, E. P. (2014). Autoantigeninduced focusing of vβ13+ T cells precedes onset of autoimmune diabetes in the LEW.1WR1 rat.
Diabetes, 63(2)
Ellerman KE, Like AA, Susceptibility to diabetes is widely distributed in normal class IIu
haplotype rats, 2000, Diabetologia.43(7):890–898
Elshebani A, Olsson A, Westman J, Tuvemo T, Korsgren O, Frisk G: Effects on isolated human
pancreatic islet cells after infection with strains of enterovirus isolated at clinical presentation of
type 1 diabetes, 2007, Virus Res 124: 193–203
Emma HW, Peter D , Yang D Huiming , Mice Spontaneously Developed in Nonobese Can
Activate Autoreactive T Cells Microparticles Are Immunostimulatory and Insulinoma-Released,
2011, J Immunol,187:1591-1600
Eto K, Tsubamoto Y, Terauchi Y, Sugiyama T, Kishimoto T, Takahashi N, Yamauchi N, Kubota
N, Murayama S, Aizawa T, Akanuma Y, Aizawa S, Kasai H, Yazaki Y, Kadowaki Ferdaoussi M,
Abdelli S, Yang JY, Cornu M, Niederhauser G, Favre D, Widmann C, Regazzi R, Thorens B,
Waeber G, Abderrahmani A. Exendin-4 protects beta-cells from interleukin-1 beta-induced
apoptosis by interfering with the c-Jun NH2-terminal kinase pathway,2008, Diabetes,57(5):1205–
15
Filippi CM, Von Herrath MG: Viral trigger for type 1 diabetes: pros and cons,2008, Diabetes 57:
2863– 2871
Flodstrom M, Tyrberg B, Eizirik DL, Sandler S. Reduced sensitivity of inducible nitric oxide
synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes,1999,
Diabetes,48(4):706–13
Floyd JC, Jr, Fajans SS, Pek S, Chance RE. A newly recognized pancreatic polypeptide: plasma
levels in health and disease, 1976, Recent Prog Horm Res, 33:519–570
Fontana L, Klein S. Aging, Adiposity, and Calorie Restriction. JAMA. 2007;297(9):986–994.
Forrest JM, Menser MA, Burgess JA: High frequency of diabetes mellitus in young adults with
congenital rubella, 1971, Lancet 2: 332–334
73

Francesco C, Francesco C, Angelika M, Matteo M,Annalisa I, Maria F,,Stefano T, Domenico
C,Mariapina P, Sante D. Pierdomenico,Mario DG , Franco C, and Andrea Mezzetti,Fredrickson,
D.S., Levy, R.I., and Lees, R.S, Fat transport in lipoproteins – an integrated approach to
mechanisms and disorders.,1967,N EngJMed, 276(1), 34-42.
Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic β-cell
dysfunction in diabetes. Role of NADH shuttle system in glucose-induced activation of
mitochondrial metabolism and insulin secretion,2013, Diabetes Rev,9(1):25–5
Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ,
Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ. Lower blood
glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor mice,
2003, Proc Natl Acad Sci U S A,100(3):1438–1443.
Glaser B, Zoghlin G, Pienta K, Vinik AI, Pancreatic polypeptide response to secretin in obesity:
effects of glucose intolerance, 1988, Metab Res, 20(5):288-9
Granata R, Settanni F, Biancone L, Trovato L, Nano R, Bertuzzi F, Destefanis S, Annunziata M,
Martinetti M, Catapano F, Ghè C, Isgaard J, Papotti M, Ghigo E, Muccioli G, Acylated and
unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human
islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A, extracellular signalregulated kinase 1/2, and phosphatidylinositol 3-Kinase/Akt signaling. 2007, Endocrinology,
148(2):529
Green A,Patterson C C,Trends in the incidence of childhood-onset diabetes in Europe 19891998,2001,Diabetologia, 44(3), 3–8.
Group, D. S. Effect of intensive therapy on residual beta-cell function in patients with type 1
diabetes in the diabetes control and complications trial. A randomized, controlled trial. The
Diabetes Control and Complications Trial Research Group,1998, Ann Intern Med ,128: 517–523,
Harms RZ, Yarde DN, Guinn Z, Lorenzo-Arteaga KM, Corley KP, Cabrera MS, Sarvetnick NE,
Increased expression of IL-18 in the serum and islets of type 1 diabetics.,2015, Mol
Immunol,64(2):306–312.
Hawa MI, Beyan H, Buckley LR, Leslie RDG, Impact of genetic and non-genetic factors in type
1 diabetes,2002, Am J Med Genet, 115: 8– 17
Hayden MS, Ghosh S.Shared Principles in NF-κB Signaling ,2008,Cell, 132(3), 344–362.
Heitmeier MR, Scarim AL, Corbett JA. Interferon-gamma increases the sensitivity of islets of
Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1, 1997, J Biol
Chem,272(21):13697–704
Henquin, J. C. The dual control of insulin secretion by glucose involves triggering and amplifying
pathways in beta-cells, 2011, Diabetes Res. Clin. Pract,93: S27–31
Hochstrasser M, Origin and function of ubiquitin-like proteins, 2009, Nature 458:422-429
74

Honeyman MC, Stone NL, Harrison LC: T-cell epitopes in type 1 diabetes autoantigen tyrosine
phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents, 1998, Mol
Med 4: 231–239,
Hostens K, Pavlovic D, Zambre Y, Ling Z, Van Schravendijk C, Eizirik DL, Pipeleers DG.
Exposure of human islets to cytokines can result in disproportionately elevated proinsulin
release.,1999, J Clin Invest,104(1):67–72.
Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases,2008, Nat Rev
Immunol,8:923–934.
Hotamisligil GS. Inflammation and metabolic disorders, 2006, Nature, 444:860–867
Huml M, Kobr J, Siala K, Varvařovská J, Pomahačová R, Karlíková M, Sýkora J, Gut Peptide
Hormones and Pediatric Type 1 Diabetes Mellitus, 2011, Physiol. Res, 60: 647-658
Hyoty H, Hiltunen M, Knip M, Laakkonen M, Vahasalo P, Karjalainen J, Koskela P, Roivainen
M, Leinikki P, Hovi T, A prospective study of the role of coxsackie B and other enterovirus
infections in the pathogenesis of IDDM: Childhood Diabetes in Finland (DiMe) Study Group,
1995, Diabetes 44: 652–657
Hyoty H, Leinikki P, Reunanen A, Ilonen J, Surcel HM, Rilva A, Kaar ML, Huupponen T,
Hakulinen A, Makela AL,Mumps infections in the etiology of type 1 (insulin-dependent) diabetes,
1988, Diabetes Res 9: 111–116
Hyoty H, Taylor KW: The role of viruses in human diabetes, 2002, Diabetologia 45: 1353–1361
Itahana Y,Itahana K, Emerging roles of p53 family members in glucose metabolism. ,2018,
International Journal of Molecular Sciences, 19(3), 1–22
Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka
Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F,
Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y, Fujino M, Free fatty acids regulate insulin
secretion from pancreatic beta cells through GPR40, 2003, Nature, 422(6928):173-6.
Jump DB. Fatty acid regulation of hepatic lipid metabolism,2011, Curr Opin Clin Nutr Metab
Care, 14(2):115–120.
Jump DB. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription, 2008, Curr Opin
Lipidol, 19:242–247
Kimmel J R,Hayden LJ,Pollock, H G, Isolation and characterization of a new pancreatic
polypeptide hormone,1975, Journal of Biological Chemistry, 250(24), 9369–9376.
Kimpimaki T, Kupila A, Hamalainen AM, Kukko M, Kulmala P, Savola K, Simell T, Keskinen
P, Ilonen J, Simell O, Knip M, The first signs of beta-cell autoimmunity appear in infancy in
genetically susceptible children from the general population: the Finnish Type 1 Diabetes
Prediction and Prevention Study, 2001 ,J Clin Endocrinol Metab 86: 4782–4788
75

Kolb H, Kolb-Bachofen V, Nitric oxide in autoimmune disease: cytotoxic or regulatory
mediator?1998, Immunology, 19(12):556-61.
Korsgren S, Molin Y, Salmela K, Lundgren T, Melhus A, Korsgren, On the etiology of type 1
diabetes: a new animal model,2012, Diabetologia ,60:346–353
Lee LF, Xu B, Michie SA, Beilhack GF, Warganich T, Turley S, McDevitt HO,The role of TNFalpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic
cell maturation,2005, Proc Natl Acad Sci U S A. 102(44):15995–16000.
Leiter EH, Von Herrath M, Elsner M, Animal models have little to teach us about T1D2 In
opposition to this proposal,2004, Diabetologia 47:1657-1660
Lenzen S, Tiedge M, Elsner M, Lortz S, Weiss H, Jörns A, Klöppel G, Wedekind D, Prokop CM,
Hedrich HJ.The LEW.1AR1/Ztm-iddm rat: a new model of spontaneous insulin-dependent
diabetes mellitus,2004, Diabetologia,, 44(9),1189-96
Levisetti MG, Suri A, Petzold SJ, Unanue ER. The insulin-specific T cells of nonobese diabetic
mice recognize a weak MHC-binding segment in more than one form, 2007, J Immunol,
178:6051–6057
Liesner R, Field techniques used by Missouri Botanical Garden. 1995, The Lancet, 358(9277),
221–229.
Lim C B, Zhang D, Lee CG , FAT10, a gene up-regulated in various cancers, is cell-cycle
regulated.,2006,Cell Division, 1, 1–6.
Liu LB, Omata W, Kojima I, Shibata H, The SUMO conjugating enzyme Ubc9 is a regulator of
GLUT4 turnover and targeting to the insulin-responsive storage compartment in 3T3-L1
adipocytes, 2007, Diabetes 56:1977-1985
Liu Z, Cort L, Eberwine R, Herrmann T, Leif JH, Greiner DL, Yahalom B, Blankenhorn EP,
Mordes JP. Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor
antibody: Vβ13 as a therapeutic target and biomarker, 2012, Diabetes, 61:1160–1168
Lonnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, Savola K, Muona P, Simell T,
Koskela P, Hyoty H: Enterovirus infection as a risk factor for beta-cell autoimmunity in a
prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study,2002,
Diabetes 49: 1314–1318
MacDonald PE, El-kholy W, Riedel M J, Salapatek AMF, Light, P E, Wheeler, M, The multiple
actions of GLP-1 on the process of glucose-stimulated insulin secretion. ,2002, Diabetes,
51: S434-S442

76

MacDonald PE, Salapatek AM, Wheeler MB,Glucagon-like peptide-1 receptor activation
antagonizes voltage-dependent repolarizing K (+) currents in beta-cells: a possible glucosedependent insulinotropic mechanism, 2002, Diabetes, 51 Suppl 3: S443-73
Maclean, N. & R. F. Ogilvie. Quantitative estimation of the pancreatic islet tissue in diabetic
subjects,1955, Diabetes, 4: 367–376,
Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent
the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and
function, 2003, Diabetes, 52(3):726–33
Maedler, K.Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in
human pancreatic islets, 2002, J. Clin. Invest. 110: 851–860
Magnuson AM, Thurber GM, Kohler RH, Weissleder R, Mathis D, Benoist C. Population
dynamics of islet-infiltrating cells in autoimmune diabetes, 2015, Proc Natl Acad Sci U S A.
,112(5):1511–1516.
Makini S, Muraoka Y, Kishimoto Y,Genetic analysis for insulitis in NOD mice, 1985,Exp Anim
,34:425-432
Marshall S, Role of Insulin, Adipocyte Hormones, and Nutrient-Sensing Pathways in Regulating
Fuel Metabolism and Energy Homeostasis: A Nutritional Perspective of Diabetes, Obesity, and
Cancer, 2006,Science,(346).
Miyazaki T, Uno M, Uehira M, Kikutani H,Kishimoto T,Kimoto M,Nishimoto H,Direct evidence
for the contribution of the unique I-ANOD to the development of insulitis in non-obese diabetic
mice, 1990, Nature, 345:722–724
Moffitt, J. H. Adverse physicochemical properties of tripalmitin in beta cells lead to morphological
changes and lipotoxicity in vitro, 2005, Diabetologia 48: 1819–1829
Mordes JP, Guberski DL, Leif JH, Woda BA, Flanagan JF, Greiner DL, Kislauskis EH, Tirabassi
RS, LEW.1WR1 Rats Develop Autoimmune Diabetes Spontaneously and in Response to
Environmental Perturbation,2005, Diabetes5,4(9):2727-33.
Obesity and Overweight,Diabetes, 2014, WorldHealth Organ. Geneva: WHO Media Centre,63(2):
596
Ole S, Birgitte B, Jorgen R, Amylin A: A Novel Approach in the Treatment of Diabetes, 2004,
Diabetes ,53: S233-S238.
Ortis F, Naamane N, Flamez D, Ladrie L, Moore F, Cunha D,Eizirik D L.Cytokines interleukin1b and TNF-a regulate different transcriptional and alternative splicing networks in primary beta
cells. 2010, Diabetes, 59, 358–374.
Pak CY, Eun HM, McArthur RG, Yoon JW: Association of cytomegalovirus infection with
autoimmune type 1 diabetes,1988, Lancet 2: 1–4
77

Pournaghi P, Sadrkhanlou RA, Hasanzadeh S, Foroughi A. An investigation on body weights,
blood glucose levels and pituitary-gonadal axis hormones in diabetic and metformin-treated
diabetic female rats, 2012, Vet Res Forum, 3(2):79–84
Pugliese A,Insulitis in the pathogenesis of type 1 diabetes,2016,Pediatric Diabetes, 17(6), 31–36
Qaisar N, Lin S, Ryan G, Yang C, Oikemus S R, Brodsky M H,Wang, J. P,A critical role for the
type i interferon receptor in virus-induced autoimmune diabetes in rats.,2017, Diabetes, 66(1),
145–157
Rat, L. E. W. Z., Gu, A., Wedekind, D., & Tiedge, M, Immune Cell Infiltration, Cytokine
Expression,2005, Diabetes,54(7), 2041–2052
Robertson M D, Jackson KG, Fielding, BA, Williams CM, Frayn, KN, Acute effects of meal fatty
acid composition on insulin sensitivity in healthy post-menopausal women, ,2002, British Journal
of Nutrition, 88(6), 635–640
Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. 2003,
Diabetologia, 46(3):305–21.
Roivainen M: Enteroviruses: new findings on the role of enteroviruses in type 1 diabetes, 2006,
Int J Biochem Cell Biol 38: 721–725
Rome S, Meugnier E, Vidal, H,The ubiquitin-proteasome pathway is a new partner for the control
of insulin signaling,2004,Current Opinion in Clinical Nutrition & Metabolic Care, 7(3).
Rui L, Yuan M, Frantz D, Shoelson S, White MF, SOCS-1 and SOCS-3 block insulin signaling
by ubiquitin-mediated degradation of IRS1 and IRS2, 2002, J.Biol Chem 277:42394-42398
Rys-Sikora KE, Gill DL. Fatty acid-mediated calcium sequestration within intracellular calcium
pools, 1998, J Biol Chem, 273(49):32627–35
Sener A, Malaisse WJ, L-leucine and a non-metabolized analogue activate pancreatic islet
glutamate dehydrogenase, 1980, Nature, 288(5787):187-9
Skowera A, Ellis RJ, Varela-Calviño R, Arif S, Huang GC, Van-Krinks C, Zaremba A, Rackham
C, Allen JS, Tree TI, Zhao M, Dayan CM, Sewell AK, Unger WW, Drijfhout JW, Ossendorp F,
Roep BO, Peakman M. CTLs are targeted to kill beta cells in patients with type 1 diabetes through
recognition of a glucose-regulated preproinsulin epitope,2008,J Clin Invest ,118(10):3390-402.
Sosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth G,
Skyler JS,Trends of earlier and later responses of C-peptide to oral glucose challenges with
progression to type 1 diabetes in diabetes prevention trial-type 1 participants, 2010, Diabetes Care.
33:620–2
Sparre T, Larsen MR, Heding PE, Karlsen AE, Jensen ON, Pociot F. Unraveling the pathogenesis
of type 1 diabetes with proteomics: present and future directions,2005, Mol Cell
Proteomics,4(4):441–57
78

Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JDJ
Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted
rat.,1996, Clin Invest,97(12):2728-35.
Sunil G. Sheth, MD; Fredric D. Gordon, MD; Sanjiv Chopra, MD, Nonalcoholic Steatohepatitis,
,1997, Ann Intern Med. 126:137–145
Takamura T, Kato I, Kimura N, Nakazawa T, Yonekura H, Takasawa S, Okamoto H. Transgenic
mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulindependent diabetes without insulitis,1998, J Biol Chem,273(5):2493–6
Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in
the U.S.: a propensity scores matching method,2010, PLoS One. 5(7): e11501.
Thivolet C, Bendelac A, Bedossa P, Bach JF, Carnaud C. CD8+ T cell homing to the pancreas in
the nonobese diabetic mouse is CD4+ T cell-dependent,1991, J Immunol, 146(1):85–8
Thomas HE, Darwiche R, Corbett JA, Kay TW. Interleukin-1 plus gamma-interferon-induced
pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production, 2002,
Diabetes,51(2):311–6
Thomas HE, Graham KL, Chee J, Thomas R, Kay TW, Krishnamurthy B. Proinflammatory
cytokines contribute to development and function of regulatory T cells in type 1 diabetes, Ann N
Y ,2013, Acad Sci. 1283:81-6.
Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to
insulin-dependent diabetes mellitus,1987, Nature 329:599–604
Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field
SF, Payne F, Lowe CE, Szeszko JS, Hafler JP, Zeitels L, Yang JH, Vella A, Nutland S, Stevens
HE, Schuilenburg H, Coleman G, Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam
AA, Ovington NR, Allen J, Adlem E, Leung HT, Wallace C, Howson JM, Guja C, IonescuTîrgovişte C., Genetics of Type 1 Diabetes in Finland, Simmonds MJ, Heward JM, Gough SC,
Wellcome Trust Case Control Consortium, Dunger DB, Wicker LS, Clayton DG : Robust
associations of four new chromosome regions from genome-wide analyses of type 1 diabetes,2007,
Nat Genet ,39: 857– 864
Todd JA: From genome to aetiology in a multifactorial disease, type 1 diabetes,1999, BioEssays;
21:164– 174
Todoric J, Antonucci L, Karin M.Targeting Inflammation in Cancer Prevention and Therapy,2016,
Cancer Prev Res (Phila),9(12):895–905
Toshinari T, Ichiro K, Noriko K, Tetsuya N, Hideto Y, Shin T, Hiroshi O,Transgenic Mice
Overexpressing Type 2 Nitric-oxide Synthase in Pancreatic b Cells Develop Insulin-dependent
Diabetes without Insulitis,,1998,The Journal Of Biological Chemistry,Vol. 273, No. 5, pp. 2493–
2496

79

Truong N, Love-Rutledge S, Lydic T,Olson LK, Effect of interferon gamma on neutral lipid levels,
lipid droplet formation, and antiviral responses in pancreatic islets and INS-1 β cells, ,2019,The
FASEBJournal,33 654.11-654.11.
Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a road map to
lipotoxicity,2010, Trends Endocrinol Metab, 21:345–352
Valle A, Giamporcaro GM, Scavini M,Reduction of circulating neutrophils precedes and
accompanies type 1 diabetes,2013, Diabetes 62:2072–2077
Wang MY, Chen L, Clark GO, Lee Y, Stevens RD, Ilkayeva OR, Wenner BR, Bain JR, Charron
MJ, Newgard CB, Unger RH. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad
Sci U S A. 2010 Mar 16;107(11):4813-9
Wang ZL, Bennet WM, Ghatei MA, Byfield PG, Smith DM, Bloom SR, Influence of islet amyloid
polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused
rat islets,1993, Diabetes,42 :330 –335
Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in
human type 1 diabetes,2009, Clin Exp Immunol,155(2):173–181.
Wurst W, Rothermel E, Gunther E, Genetic mapping of C4 and Bf complement genes in the rat
major histocompatibility complex,1988, Immunogenetics ,28: 57– 60
Yang XD, Tisch R, Singer SM, Effect of tumor necrosis factor alpha on insulin-dependent diabetes
mellitus in NOD mice:The early development of autoimmunity and the diabetogenic
process,1994,J Exp Med. 180(3):995–1004.
Ylipaasto P, Klingel K, Lindberg AM, Otonkoski T, Kandolf R, Hovi T, Roivainen M: Enterovirus
infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured
islet beta cells, 2004, Diabetologia 47: 225–239
Yokoi N, Hidaka S, Tanabe S, Role of major histocompatibility complex class II in the
development of autoimmune type 1 diabetes and thyroiditis in rats,2012, Genes Immune; 13:139–
145
Yoon JW, Austin M, Onodera T, Notkins AL, Isolation of a virus from the pancreas of a child
with diabetic ketoacidosis, 1979, N Engl J Med 300: 1173–1179
Yu C, Chen R, Li JJ, Li J J, Drahansky M, Beta-Cell Function and Failure in Type 1 Diabetes,
Type 1 Diabetes,2012, 13

80

